[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5028
1. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol; 2010 Sep 20;28(27):4177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
  • PURPOSE: Human T-cell lymphotropic virus type-I-associated adult T-cell leukemia/lymphoma (ATL) is an aggressive, chemotherapy-resistant malignancy.
  • RESULTS: According to Shimoyama classification, there were 116 patients with acute ATL, 18 patients with chronic ATL, 11 patients with smoldering ATL, and 100 patients with ATL lymphoma.
  • Patients with acute, chronic, and smoldering ATL significantly benefited from first-line antiviral therapy, whereas patients with ATL lymphoma experienced a better outcome with chemotherapy.
  • In acute ATL, achievement of complete remission with antiviral therapy resulted in 82% 5-year survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Survivors

  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Dec 20;28(36):e765; author reply e766 [20921454.001]
  • (PMID = 20585095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


2. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • ALL subtypes included an early pre-B phenotype (15%), a common phenotype (45%), a pre-B phenotype (5%), a mature B phenotype (11%), and a T phenotype (24%).
  • CNS involvement at diagnosis was observed in 18 patients (3.9%).
  • The only 2 survivors underwent stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Bellaaj H, Moussa A, Gouiaa N, Maazoun K, Frikha I, Medhaffar M, Hdiji S, Elloumi M, Souissi T: [Isolated extramedullary adnexal relapse of acute lymphoblastic leukemia: a case report]. Arch Pediatr; 2009 Jul;16(7):1016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolated extramedullary adnexal relapse of acute lymphoblastic leukemia: a case report].
  • [Transliterated title] Rechute extramédullaire annexielle isolée d'une leucémie aiguë lymphoblastique : à propos d'un cas.
  • The occurrence of an isolated ovarian or pelvic relapse of acute lymphoblastic leukemia (ALL) in complete remission after chemotherapy has rarely been described.
  • The diagnosis was established by a CT-guided biopsy.
  • [MeSH-major] Fallopian Tubes / pathology. Leukemic Infiltration / diagnosis. Ovary / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19359147.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Gorello P, La Starza R, Varasano E, Chiaretti S, Elia L, Pierini V, Barba G, Brandimarte L, Crescenzi B, Vitale A, Messina M, Grammatico S, Mancini M, Matteucci C, Bardi A, Guarini A, Martelli MF, Foà R, Mecucci C: Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults. Haematologica; 2010 Jan;95(1):79-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults.
  • BACKGROUND: Molecular lesions in T-cell acute lymphoblastic leukemias affect regulators of cell cycle, proliferation, differentiation, survival and apoptosis in multi-step pathogenic pathways.
  • Full genetic characterization is needed to identify events concurring in the development of these leukemias.
  • DESIGN AND METHODS: We designed a combined interphase fluorescence in situ hybridization strategy to study 25 oncogenes/tumor suppressor genes in T-cell acute lymphoblastic leukemias and applied it in 23 adult patients for whom immunophenotyping, karyotyping, molecular studies, and gene expression profiling data were available.
  • The results were confirmed and integrated with those of multiplex-polymerase chain reaction analysis and gene expression profiling in another 129 adults with T-cell acute lymphoblastic leukemias.
  • It found abnormalities known to be associated with T-cell acute lymphoblastic leukemias, i.e.
  • Multiplex-polymerase chain reaction analysis and gene expression profiling of 129 further cases found five additional cases of TAF_I-NUP214-positive T-cell acute lymphoblastic leukemia.
  • CONCLUSIONS: Our combined interphase fluorescence in situ hybridization strategy greatly improved the detection of genetic abnormalities in adult T-cell acute lymphoblastic leukemias.
  • The estimated incidence of TAF_I-NUP214, a new recurrent fusion in adult T-cell acute lymphoblastic leukemias, was 4.6% (7/152).
  • [MeSH-major] Comparative Genomic Hybridization. Genetic Heterogeneity. In Situ Hybridization, Fluorescence. Leukemia-Lymphoma, Adult T-Cell / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Jun 21;26(29):4306-18 [17237825.001]
  • [Cites] Haematologica. 2007 May;92(5):619-26 [17488685.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4322-8 [18172006.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):751-8 [18362173.001]
  • [Cites] Blood. 2008 May 1;111(9):4668-80 [18299449.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):153-68 [18691165.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Haematologica. 2003 Mar;88(3):275-9 [12651265.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4089-98 [15205317.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 [2034676.001]
  • [Cites] Exp Cell Res. 1998 May 1;240(2):274-81 [9597000.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Mol Biol. 1999 Jul 9;290(2):547-57 [10390352.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4849-52 [15713800.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1116-27 [16079112.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1948-57 [16107895.001]
  • [Cites] Leukemia. 2006 Jan;20(1):82-6 [16270038.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1184-7 [16572206.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1238-44 [16673021.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1248-51 [16956826.001]
  • [Cites] Haematologica. 2007 Feb;92(2):232-5 [17296573.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • (PMID = 20065082.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2805748
  •  go-up   go-down


5. Kode J, Dudhal N, Banavali S, Chiplunkar S: T-cell receptor gamma and delta junctional gene rearrangements as diagnostic and prognostic biomarker for T-cell acute lymphoblastic leukemia. Leuk Lymphoma; 2006 Apr;47(4):769-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell receptor gamma and delta junctional gene rearrangements as diagnostic and prognostic biomarker for T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Biomarkers, Tumor. Gene Rearrangement. Leukemia, T-Cell / diagnosis. Leukemia, T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell, gamma-delta / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886283.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


6. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L: Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia; 2006 Mar;8(3):223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.
  • Assay of these molecules by enzyme-linked immunosorbent assay in patients suffering from another hematologic disorder (acute leukemia) highlights increased sHLA-G secretion.
  • This increased secretion seems more marked in acute leukemia subtypes affecting monocytic and lymphoid lineages such as FABM4 and FABM5, as well as both B and T acute lymphoblastic leukemia (ALL).
  • All these findings suggest that sHLA-G molecules could be a factor in tumoral escape from immune survey during acute leukemia.
  • [MeSH-major] Antigens, Neoplasm / blood. HLA Antigens / blood. Histocompatibility Antigens Class I / blood. Leukemia / blood
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / chemistry. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cytokines / blood. Cytokines / pharmacology. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Leukemic / drug effects. HLA-G Antigens. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / classification. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retrospective Studies. Solubility. Tumor Escape

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jun 15;164(12):6100-4 [10843658.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):379-85 [14708718.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):280-2 [11091213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1102-7 [11137213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1138-49 [11137219.001]
  • [Cites] Hum Immunol. 2000 Dec;61(12):1347-51 [11163092.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6133-9 [11087747.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):369-76 [11466692.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5 [11572934.001]
  • [Cites] Nephrologie. 2003;24(8):451-6 [14737978.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9145-9 [3480534.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51 [1570318.001]
  • [Cites] Cell Immunol. 1994 May;155(2):312-22 [8181068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4209-13 [8183892.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5516-24 [7989753.001]
  • [Cites] Tissue Antigens. 1996 Nov;48(5):609-14 [8988550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54 [9144223.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):289-98 [9221758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11520-5 [9326642.001]
  • [Cites] Eur J Immunol. 1997 Dec;27(12):3380-8 [9464826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1980-90 [9645380.001]
  • [Cites] Hum Immunol. 1998 Aug;59(8):524-8 [9712358.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):277-83 [9933109.001]
  • [Cites] Tissue Antigens. 1999 Jan;53(1):14-22 [10082427.001]
  • [Cites] Int Immunol. 1999 May;11(5):803-11 [10330285.001]
  • [Cites] Am J Reprod Immunol. 1999 Jul;42(1):30-6 [10429764.001]
  • [Cites] J Reprod Immunol. 1999 Jul;43(2):105-9 [10479047.001]
  • [Cites] Autoimmun Rev. 2005 Nov;4(8):503-9 [16214086.001]
  • [Cites] Hum Immunol. 2005 Aug;66(8):853-63 [16216668.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3576-86 [12516543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):125-34 [12594841.001]
  • [Cites] Leuk Res. 2003 Jul;27(7):643-8 [12681364.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):752-61 [12878353.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):802-10 [12878359.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1017-24 [14602230.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1093-101 [14602240.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):606-11 [14697234.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):343-51 [14708714.001]
  • [Cites] Ann Neurol. 2000 Oct;48(4):679-84 [11026456.001]
  • (PMID = 16611416.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC1578523
  •  go-up   go-down


7. Wang X, Yuling H, Yanping J, Xinti T, Yaofang Y, Feng Y, Ruijin X, Li W, Lang C, Jingyi L, Zhiqing T, Jingping O, Bing X, Li Q, Chang AE, Sun Z, Youxin J, Jinquan T: CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells. J Immunol; 2007 Sep 1;179(5):2880-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells.
  • In a previous study, we have reported that ligation of CCL19-CCR7 and CXCL13-CXCR5 activates paternally expressed gene 10 (PEG10), resulting in an enhancement of apoptotic resistance in B-cell acute lymphocytic leukemia (B-ALL) CD23+CD5+ B cells.
  • CCL19/CXCL13-activated B-ALL CD23+CD5+ B cells, in turn, increase IL-10 expression in syngeneic CD8+ T cells in a B cell-derived IL-10-dependent manner and requiring a cell-cell contact.
  • Moreover, using a short hairpin RNA to knockdown PEG10, we provide direct evidence that increased expression of PEG10 in B-ALL CD23+CD5+ B cells is involved in malignant B-T cell interaction, contributing to the up-regulation of IL-10 expression, as well as to the impairment of cytotoxicity of syngeneic CD8+ T cells.
  • [MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / immunology. CD8-Positive T-Lymphocytes / immunology. Chemokine CCL19 / physiology. Chemokine CXCL13 / physiology. Immunologic Surveillance / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2007 Nov 15;179(10):7184
  • (PMID = 17709502.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / CXCL13 protein, human; 0 / Chemokine CCL19; 0 / Chemokine CXCL13; 0 / PEG10 protein, human; 0 / Proteins; 0 / RNA, Small Interfering; 0 / Receptors, IgE; 130068-27-8 / Interleukin-10
  •  go-up   go-down


8. Sakamoto Y, Mariya Y, Sasaki S, Teshiromori R, Oshikiri T, Segawa M, Ogura K, Akagi T, Kubo K, Kaimori M, Funato T: WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia. Tohoku J Exp Med; 2009 Oct;219(2):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
  • The Wilms' tumor gene 1 (WT1) encodes a transcription factor that is involved in normal cellular development and cell survival.
  • WT1 mRNA is overexpressed in the minimal residual disease (MRD) of patients with hematopoietic malignancy patients, particularly acute myeloid leukemia (AML).
  • MRD represents the condition with the low levels of leukemia cells in the bone marrow and is known as a sign of recurrence.
  • The patients included AML (55 patients), acute lymphoblastic leukemia (11), myelodysplastic syndrome (20), malignant lymphoma (5), chronic myeloid leukemia (1), prostatic carcinoma (1), and leukopenia (2).
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics. Neoplasm, Residual / genetics. WT1 Proteins / blood. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776535.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / WT1 Proteins
  •  go-up   go-down


9. Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J: The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk Res; 2006 May;30(5):575-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heat shock protein 90 (Hsp90) serves as a chaperone for a number of cell signaling proteins, including many tyrosine and serine/threonine kinases, which are involved in proliferation and/or survival.
  • KIT is the receptor for stem cell factor (SCF) and required for normal hematopoiesis.
  • Mutations in c-Kit result in ligand-independent tyrosine kinase activity and uncontrolled cell proliferation.
  • Kasumi-1 is t(8;21) acute myeloid leukemia (AML) cell line harboring mutated KIT with Asn822Lys substitution.
  • [MeSH-major] Apoptosis / drug effects. Benzoquinones / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Asparagine / genetics. Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Down-Regulation / drug effects. HL-60 Cells. Humans. Lysine / genetics. Mutation. RNA, Messenger / drug effects. RNA, Messenger / genetics. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. L-Lysine .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213582.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / RNA, Messenger; 4GY0AVT3L4 / tanespimycin; 7006-34-0 / Asparagine; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; K3Z4F929H6 / Lysine
  •  go-up   go-down


10. de Witte T, Suciu S, Brand R, Muus P, Kröger N: Autologous stem cell transplantation in myelodysplastic syndromes. Semin Hematol; 2007 Oct;44(4):274-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in myelodysplastic syndromes.
  • Allogeneic stem cell transplantation (SCT) is the treatment of choice for the majority of young patients with myelodysplasia (MDS) who have a histocompatible donor (sibling or unrelated donor).
  • For some patients lacking a human leukocyte antigen (HLA)-compatible donor, chemotherapy followed by autologous SCT may be a reasonable alternative, especially for patients with therapy-related MDS/acute myeloid leukemia (AML).
  • Mobilized peripheral blood stem cells are the preferred stem cell source for young patients, especially in view of the more rapid hematopoietic recovery after transplantation with mobilized stem cells, but bone marrow stem cells also may be considered for patients older than 50 years.
  • [MeSH-major] Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Disease-Free Survival. Evidence-Based Medicine. Hematopoietic Stem Cell Mobilization. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction. Risk Assessment. Transplantation, Autologous / methods. Transplantation, Homologous / methods


11. Bae SY, Yoon SY, Huh JH, Sung HJ, Choi IK: Hypereosinophilia in biphenotypic (B-cell/T-cell) acute lymphoblastic leukemia. Leuk Lymphoma; 2007 Jul;48(7):1417-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypereosinophilia in biphenotypic (B-cell/T-cell) acute lymphoblastic leukemia.
  • [MeSH-major] Hypereosinophilic Syndrome / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


12. Ando T, Mitani N, Matsui K, Yamashita K, Nomiyama J, Tsuru M, Yujiri T, Tanizawa Y: Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity. Int J Hematol; 2009 Oct;90(3):374-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity.
  • Isolated extramedullary (EM) relapse of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare.
  • Predisposing factors include CD56 expression and the chromosomal abnormality t(8;21).
  • We describe an AML patient showing the chromosomal abnormality t(8;21) and CD56 expression who experienced a unique EM relapse after allo-HSCT.
  • These findings suggest that the graft-versus-leukemia effect may preferentially maintain marrow remission rather than prevent EM relapse.
  • In addition, our findings show that extended survival is possible after EM relapse following allo-HSCT in patients with marrow hematopoiesis of donor origin, and that augmentation of the graft-versus-leukemia effect may be useful.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute. Stomach Neoplasms. Translocation, Genetic


13. Cossu F: Genetics of SCID. Ital J Pediatr; 2010;36:76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human SCID (Severe Combined Immunodeficiency) is a prenatal disorder of T lymphocyte development, that depends on the expression of numerous genes.
  • The knowledge of the genetic basis of SCID is essential for diagnosis (e.g., clinical phenotype, lymphocyte profile) and treatment (e.g., use and type of pre-hematopoietic stem cell transplant conditioning).Over the last years novel genetic defects causing SCID have been discovered, and the molecular and immunological mechanisms of SCID have been better characterized.
  • Distinct forms of SCID show both common and peculiar (e.g., absence or presence of nonimmunological features) aspects, and they are currently classified into six groups according to prevalent pathophysiological mechanisms: impaired cytokine-mediated signaling; pre-T cell receptor defects; increased lymphocyte apoptosis; defects in thymus embryogenesis; impaired calcium flux; other mechanisms.This review is the updated, extended and largely modified translation of the article "Cossu F: Le basi genetiche delle SCID", originally published in Italian language in the journal "Prospettive in Pediatria" 2009, 156:228-238.
  • [MeSH-minor] Genetic Therapy. Genotype. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Neonatal Screening. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 2005 Jan;146(1):137-40 [15644840.001]
  • [Cites] Immunol Rev. 2005 Feb;203:110-26 [15661025.001]
  • [Cites] Immunol Rev. 2005 Feb;203:127-42 [15661026.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):537-47 [15665844.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4179-86 [15731174.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):2974-6 [16276411.001]
  • [Cites] Mol Genet Metab. 2005 Dec;86(4):427-30 [16260163.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6323-9 [12055248.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):765-8 [12437656.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):477-88 [12835668.001]
  • [Cites] J Allergy Clin Immunol. 2004 Apr;113(4):734-41 [15100681.001]
  • [Cites] Ann Hum Genet. 2004 May;68(Pt 3):265-8 [15180707.001]
  • [Cites] Lancet. 2004 Jun 19;363(9426):2051-4 [15207958.001]
  • [Cites] Pediatr Res. 1977 Jan;11(1 Pt 2):63-89 [401538.001]
  • [Cites] Pediatr Res. 1984 Aug;18(8):723-8 [6332299.001]
  • [Cites] N Engl J Med. 1985 May 2;312(18):1151-9 [2984567.001]
  • [Cites] Cell. 1993 Apr 9;73(1):147-57 [8462096.001]
  • [Cites] J Allergy Clin Immunol. 1994 Feb;93(2):543-50 [8120281.001]
  • [Cites] Am J Med Genet. 1996 Oct 16;65(2):167-70 [8911612.001]
  • [Cites] J Pediatr. 1997 Mar;130(3):345-6 [9063405.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jan;28(1):53-6 [16394896.001]
  • [Cites] Cell. 2006 Jan 27;124(2):287-99 [16439204.001]
  • [Cites] J Pediatr. 2006 Feb;148(2):272-4 [16492442.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Allergy Clin Immunol. 2006 Apr;117(4):897-903 [16630949.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):728-40 [16998507.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:34 [16959034.001]
  • [Cites] Hum Mutat. 2006 Dec;27(12):1174-84 [16960852.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):86-92 [17187068.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2556-64 [17277165.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3198-206 [17170122.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3595-602 [17185467.001]
  • [Cites] J Allergy Clin Immunol. 2007 Aug;120(2):423-8 [17481714.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):690-702 [17703229.001]
  • [Cites] Lancet. 2007 Oct 20;370(9596):1443-52 [17950858.001]
  • [Cites] J Obstet Gynaecol Can. 2007 Nov;29(11):927-44 [17977497.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):421-9 [9664084.001]
  • [Cites] Clin Genet. 2008 Apr;73(4):380-4 [18339010.001]
  • [Cites] Annu Rev Immunol. 2008;26:355-88 [18304000.001]
  • [Cites] Annu Rev Immunol. 2008;26:233-59 [18304005.001]
  • [Cites] J Allergy Clin Immunol. 2008 Apr;121(4):1056-8 [18243287.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4209-19 [18218852.001]
  • [Cites] Clin Exp Immunol. 2008 Jul;153(1):75-80 [18505430.001]
  • [Cites] Nat Rev Immunol. 2008 Jul;8(7):545-58 [18551129.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3143-50 [18688286.001]
  • [Cites] Nat Immunol. 2008 Nov;9(11):1307-15 [18836449.001]
  • [Cites] J Immunol. 2008 Nov 1;181(9):5815-6 [18941168.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3594-600 [18669893.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2008 Dec;8(6):510-4 [18978464.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2008 Dec;8(6):534-9 [18978468.001]
  • [Cites] Eur J Pediatr. 2009 Jan;168(1):87-93 [18509675.001]
  • [Cites] Science. 2008 Dec 5;322(5907):1562-5 [19056990.001]
  • [Cites] J Allergy Clin Immunol. 2008 Dec;122(6):1219-20 [18845326.001]
  • [Cites] J Allergy Clin Immunol. 2008 Dec;122(6):1082-6 [18992930.001]
  • [Cites] Nat Genet. 2009 Jan;41(1):106-11 [19043416.001]
  • [Cites] Nat Genet. 2009 Jan;41(1):101-5 [19043417.001]
  • [Cites] J Inherit Metab Dis. 2009 Aug;32(4):459-71 [19585268.001]
  • [Cites] Adv Exp Med Biol. 2009;650:46-58 [19731800.001]
  • [Cites] Immunol Res. 2009;45(1):37-45 [19238335.001]
  • [Cites] Blood. 2009 Oct 8;114(15):3216-26 [19633200.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3524-32 [19638621.001]
  • [Cites] Nat Rev Immunol. 2009 Nov;9(11):811-6 [19809471.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):496-502 [19779332.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):503-9 [19823081.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):489-95 [19841578.001]
  • [Cites] Clin Immunol. 2009 Dec;133(3):287-94 [19740703.001]
  • [Cites] Pediatrics. 2000 Mar;105(3):E39 [10699141.001]
  • [Cites] Int Immunol. 2000 Apr;12(4):449-57 [10744646.001]
  • [Cites] Curr Opin Immunol. 2000 Aug;12(4):468-73 [10899029.001]
  • [Cites] J Immunol. 2001 Jan 15;166(2):1308-13 [11145714.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(3):227-33 [11535989.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):447-58 [19179314.001]
  • [Cites] Immunol Rev. 2009 Mar;228(1):41-57 [19290920.001]
  • [Cites] Immunol Rev. 2009 Mar;228(1):273-87 [19290934.001]
  • [Cites] Annu Rev Immunol. 2009;27:199-227 [19302039.001]
  • [Cites] Pediatr Transplant. 2009 Mar;13(2):244-50 [18822103.001]
  • [Cites] Immunol Res. 2009;43(1-3):223-42 [18979075.001]
  • [Cites] Clin Immunol. 2009 Apr;131(1):24-30 [19097825.001]
  • [Cites] Clin Immunol. 2009 May;131(2):179-88 [19217351.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4114-24 [19168787.001]
  • [Cites] Pediatrics. 2009 May;123(5):e871-7 [19403480.001]
  • [Cites] Annu Rev Immunol. 2009;27:591-619 [19132916.001]
  • [Cites] Int J Mol Sci. 2009 Apr;10(4):1729-72 [19468337.001]
  • [Cites] Acta Paediatr. 2009 Jun;98(6):1062-4 [19243569.001]
  • [Cites] Immunol Res. 2009;44(1-3):4-17 [18592143.001]
  • [Cites] Immunol Res. 2009;44(1-3):61-70 [19066739.001]
  • [Cites] Br J Haematol. 2009 Apr;145(2):164-72 [19208095.001]
  • [Cites] Nat Rev Immunol. 2009 Jul;9(7):480-90 [19543225.001]
  • [Cites] Blood. 2009 Jul 2;114(1):105-8 [19414857.001]
  • [Cites] Eur J Med Genet. 2009 Nov-Dec;52(6):373-8 [19467349.001]
  • [Cites] Gene Ther. 2009 Nov;16(11):1285-91 [19776764.001]
  • [Cites] J Pediatr. 2009 Dec;155(6):834-840.e1 [19818451.001]
  • [Cites] Nat Rev Immunol. 2009 Dec;9(12):823-32 [19935802.001]
  • [Cites] Eur J Pediatr. 2010 Mar;169(3):311-4 [19657670.001]
  • [Cites] N Engl J Med. 2010 Jan 28;362(4):314-9 [20107217.001]
  • [Cites] J Allergy Clin Immunol. 2010 Jan;125(1):209-16 [20109747.001]
  • [Cites] Immunol Allergy Clin North Am. 2010 Feb;30(1):103-24 [20113889.001]
  • [Cites] Immunol Allergy Clin North Am. 2010 Feb;30(1):125-42 [20113890.001]
  • [Cites] Nat Rev Mol Cell Biol. 2010 Mar;11(3):171-81 [20125188.001]
  • [Cites] Clin Immunol. 2010 May;135(2):183-92 [20172764.001]
  • [Cites] Clin Immunol. 2010 May;135(2):169-82 [20189884.001]
  • [Cites] Clin Immunol. 2010 May;135(2):236-46 [20236866.001]
  • [Cites] Nat Immunol. 2010 Jun;11(6):457-60 [20485269.001]
  • [Cites] Immunol Allergy Clin North Am. 2010 May;30(2):173-8 [20493394.001]
  • [Cites] Immunol Allergy Clin North Am. 2010 May;30(2):221-36 [20493398.001]
  • [Cites] Public Health Rep. 2010 May-Jun;125 Suppl 2:88-95 [20518449.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2010 Jun 11;59(22):687-8 [20535093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10097-102 [20479256.001]
  • [Cites] Immunology. 2010 Jun;130(2):166-71 [20557575.001]
  • [Cites] Am J Med Genet A. 2010 Aug;152A(8):ix [20662017.001]
  • [Cites] N Engl J Med. 2010 Jul 22;363(4):355-64 [20660403.001]
  • [Cites] Pediatrics. 2010 Aug;126(2):e465-9 [20603253.001]
  • [Cites] Blood. 2010 Aug 12;116(6):900-8 [20457870.001]
  • [Cites] J Allergy Clin Immunol. 2010 Sep;126(3):602-10.e1-11 [20673987.001]
  • [Cites] Nature. 2010 Sep 16;467(7313):318-22 [20844535.001]
  • [Cites] J Allergy Clin Immunol. 2010 Nov;126(5):1073-4 [20933257.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4198-205 [17785587.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] J Clin Immunol. 1999 Mar;19(2):87-97 [10226883.001]
  • [Cites] J Pediatr Surg. 2004 Nov;39(11):1607-15 [15547821.001]
  • (PMID = 21078154.001).
  • [ISSN] 1824-7288
  • [Journal-full-title] Italian journal of pediatrics
  • [ISO-abbreviation] Ital J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2999594
  •  go-up   go-down


14. Garbe AI, Krueger A, Gounari F, Zúñiga-Pflücker JC, von Boehmer H: Differential synergy of Notch and T cell receptor signaling determines alphabeta versus gammadelta lineage fate. J Exp Med; 2006 Jun 12;203(6):1579-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential synergy of Notch and T cell receptor signaling determines alphabeta versus gammadelta lineage fate.
  • Thymic precursors expressing the pre-T cell receptor (TCR), the gammadeltaTCR, or the alphabetaTCR can all enter the CD4+ 8+ alphabeta lineage, albeit with different efficacy.
  • In particular, in alphabeta lineage commitment, the pre-TCR synergizes more efficiently with Notch signals than the other two TCRs, whereas gammadeltaTCR-expressing cells can survive and expand in the absence of Notch signals, even though Notch signaling enhances their proliferation.
  • These observations suggest a new model of alphabeta versus gammadelta lineage choice in which lineage fate is determined by the extent of synergy between TCR and Notch signaling and in which the evolutionarily recent advent of the cell-autonomously signaling pre-TCR increased the efficacy of alphabeta T cell generation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jul 1;108(1):305-10 [16507772.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4683-7 [8643464.001]
  • [Cites] Nature. 1995 Jun 29;375(6534):795-8 [7596413.001]
  • [Cites] Immunity. 2006 Jul;25(1):105-16 [16814577.001]
  • [Cites] Cell. 1996 Jul 26;86(2):243-51 [8706129.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):524-7 [10952314.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5566-72 [11067911.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):537-48 [10952723.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3184-93 [11207271.001]
  • [Cites] Immunity. 2001 Jul;15(1):71-82 [11485739.001]
  • [Cites] Nat Rev Immunol. 2001 Dec;1(3):193-9 [11905828.001]
  • [Cites] Nat Immunol. 2002 May;3(5):483-8 [11927911.001]
  • [Cites] Immunity. 2002 Dec;17(6):749-56 [12479821.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5780-92 [14592976.001]
  • [Cites] J Exp Med. 2004 Mar 1;199(5):607-15 [14993248.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5230-9 [15100261.001]
  • [Cites] Immunity. 2004 May;20(5):611-22 [15142529.001]
  • [Cites] Adv Immunol. 2004;84:201-38 [15246254.001]
  • [Cites] Nature. 1985 Mar 7-13;314(6006):103-7 [2983227.001]
  • [Cites] Nature. 1985 May 16-22;315(6016):232-3 [3873615.001]
  • [Cites] Nature. 1987 Jun 25-Jul 1;327(6124):677-82 [2439914.001]
  • [Cites] Nature. 1988 Sep 15;335(6187):229-33 [2970593.001]
  • [Cites] J Exp Med. 1989 Mar 1;169(3):795-806 [2494291.001]
  • [Cites] Nature. 1989 Apr 13;338(6216):591-3 [2784545.001]
  • [Cites] Nature. 1989 Dec 21-28;342(6252):931-4 [2480528.001]
  • [Cites] EMBO J. 1991 Jan;10(1):93-100 [1703490.001]
  • [Cites] Cell. 1993 Oct 22;75(2):283-94 [8402912.001]
  • [Cites] Science. 1994 Nov 18;266(5188):1208-12 [7973703.001]
  • [Cites] Immunity. 1995 Jun;2(6):617-27 [7796295.001]
  • [Cites] Immunity. 1996 Oct;5(4):343-52 [8885867.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):65-75 [8977176.001]
  • [Cites] Cell. 1997 Mar 21;88(6):833-43 [9118226.001]
  • [Cites] J Exp Med. 1997 May 5;185(9):1541-7 [9151891.001]
  • [Cites] Immunity. 1997 Jul;7(1):83-95 [9252122.001]
  • [Cites] Immunity. 1998 Apr;8(4):427-38 [9586633.001]
  • [Cites] J Exp Med. 1998 Oct 19;188(8):1465-71 [9782123.001]
  • [Cites] Eur J Immunol. 1998 Nov;28(11):3456-67 [9842888.001]
  • [Cites] Immunity. 1998 Nov;9(5):649-55 [9846486.001]
  • [Cites] Immunol Rev. 1998 Oct;165:111-9 [9850856.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1440-7 [15486060.001]
  • [Cites] Immunity. 2005 May;22(5):583-93 [15894276.001]
  • [Cites] Immunity. 2005 May;22(5):595-606 [15894277.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] Immunity. 2005 Oct;23(4):431-43 [16226508.001]
  • [Cites] Nat Immunol. 2006 Jan;7(1):67-75 [16327787.001]
  • [Cites] Immunity. 2006 Jan;24(1):53-64 [16413923.001]
  • (PMID = 16754723.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI045846; United States / NCI NIH HHS / CA / P01 CA10990; United States / NIAID NIH HHS / AI / R01 AI47281; United States / NIAID NIH HHS / AI / R01 AI047281; United States / NIAID NIH HHS / AI / R01 AI45846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / Receptors, Notch; 128559-51-3 / RAG-1 protein
  • [Other-IDs] NLM/ PMC2118312
  •  go-up   go-down


15. Derré L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A, Zoete V, Romero P, Michielin O, Speiser DE, Rufer N: Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A; 2008 Sep 30;105(39):15010-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we studied T cell receptor (TCR) primary structure and function of 605 HLA-A*0201/NY-ESO-1(157-165)-specific CD8 T cell clones derived from five melanoma patients.
  • All remaining T cell clones belong to two additional sets expressing BV1 or BV13 TCRs, associated with alpha-chains with highly diverse VJ usage, CDR3 amino acid sequence, and length.
  • Yet, all T cell clonotypes recognize tumor antigen with similar functional avidity.
  • Two residues, Met-160 and Trp-161, located in the middle region of the NY-ESO-1(157-165) peptide, are critical for recognition by most of the T cell clonotypes.
  • [MeSH-major] Neoplasm Proteins / immunology. Peptide Fragments / immunology. Receptors, Antigen, T-Cell, alpha-beta / immunology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. L-Threonine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]
  • [Cites] Protein Eng Des Sel. 2007 Aug;20(8):397-403 [17644531.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):766s-772s [11300471.001]
  • [Cites] J Immunol. 2002 Apr 15;168(8):4231-40 [11937585.001]
  • [Cites] J Exp Med. 2002 Apr 15;195(8):991-1001 [11956290.001]
  • [Cites] Eur J Immunol. 2002 Nov;32(11):3181-90 [12555663.001]
  • [Cites] Annu Rev Immunol. 2003;21:659-84 [12615890.001]
  • [Cites] J Immunol. 2003 May 15;170(10):5103-9 [12734356.001]
  • [Cites] Nat Immunol. 2003 Jul;4(7):657-63 [12796775.001]
  • [Cites] Nat Rev Immunol. 2004 Feb;4(2):123-32 [15040585.001]
  • [Cites] Nature. 1974 Apr 19;248(5450):701-2 [4133807.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8987-90 [1833769.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2335-40 [7964506.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5586-92 [7527444.001]
  • [Cites] J Exp Med. 1998 May 18;187(10):1647-57 [9584143.001]
  • [Cites] J Exp Med. 2004 Dec 20;200(12):1547-57 [15596521.001]
  • [Cites] Immunity. 2005 Jan;22(1):117-29 [15664164.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):239-45 [15716973.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1243-55 [15837811.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):252-7 [15838382.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1912-6 [16488988.001]
  • [Cites] Annu Rev Immunol. 2006;24:419-66 [16551255.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6804-14 [17082594.001]
  • [Cites] Eur J Immunol. 2007 Mar;37(3):838-48 [17323415.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2368-79 [17675498.001]
  • [Cites] J Mol Biol. 2007 Sep 14;372(2):535-48 [17658550.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2047-54 [11280765.001]
  • (PMID = 18809922.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / peptide NY-ESO-1 157-165; 2ZD004190S / Threonine; AE28F7PNPL / Methionine
  • [Other-IDs] NLM/ PMC2567484
  •  go-up   go-down


16. Martínez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, Castrillo JM, Rivas C, Benítez J: Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia; 2005 Dec;19(12):2254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas.
  • Nuclear factor kappa B (NF-kappaB) is one important pathway in T-cell proliferation and survival.
  • In a previously reported microarray study, we found NF-kappaB pathway genes differentially expressed between peripheral (PTCL) and lymphoblastic lymphomas.
  • This distinction was found among all T-cell lymphoma categories analyzed (PTCL unspecified, angioimmunoblastic, cutaneous and natural killer/T lymphomas) with the exception of anaplastic lymphomas (ALCL), which were characterized by reduced NF-kappaB expression in anaplastic cells.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, T-Cell, Peripheral / genetics. NF-kappa B / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270046.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B
  •  go-up   go-down


17. Tedeschi R, Luostarinen T, Marus A, Bzhalava D, Ogmundsdottir HM, Dillner J, De Paoli P, Surcel HM, Pukkala E, Lehtinen M, Lehtinen T: No risk of maternal EBV infection for childhood leukemia. Cancer Epidemiol Biomarkers Prev; 2009 Oct;18(10):2790-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No risk of maternal EBV infection for childhood leukemia.
  • We performed a large nested case-control study within the Finnish and Icelandic maternity cohorts to verify/falsify the association of maternal EBV infection with an increased risk of acute lymphoblastic leukemia (ALL) in the offspring found in previous studies.
  • For each index mother of a leukemia case, three matched control mothers with cancer-free offspring were identified.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Pregnancy Complications, Infectious / epidemiology. Pregnancy Complications, Infectious / virology

  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755652.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Epstein-Barr viral capsid antigen
  •  go-up   go-down


18. Fujimoto K, Endo T, Nishio M, Obara M, Yamaguchi K, Takeda Y, Goto H, Kasahara I, Sato N, Koike T: Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier. Int J Hematol; 2009 Dec;90(5):601-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier.
  • The diagnosis of splenic marginal zone lymphoma (SMZL) was made by a splenectomy.
  • Two years after the splenectomy, she was admitted for an acute flare-up of hepatitis B.
  • There has been no recurrence of acute hepatitis and she has been in complete remission for SMZL for more than 6 years.
  • The clinical course of this patient suggests that an immune response against HBV also affects the clearance of lymphoma cells.
  • [MeSH-major] Hepatitis B / immunology. Lymphoma, B-Cell, Marginal Zone / virology. Remission, Spontaneous. Splenic Neoplasms / surgery

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2002 Jun;3(1):41-7 [12141954.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4643-9 [16493005.001]
  • [Cites] Eur J Haematol. 2004 May;72(5):336-41 [15059068.001]
  • [Cites] J Immunol. 1987 Aug 1;139(3):767-73 [2955050.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1146-57 [7573673.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):731-6 [8652403.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):455-66 [1599024.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):745-52 [15471561.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):3025-33 [9185527.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):95-103 [12573351.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1611-7 [9269780.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1711-6 [15284859.001]
  • [Cites] Blood. 2003 Aug 1;102(3):996-9 [12714514.001]
  • [Cites] Eur J Haematol. 2005 Feb;74(2):158-65 [15654908.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):577-90 [12007506.001]
  • (PMID = 19802732.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A, Samuel S, Tsirigotis P, Gesundheit B, Slavin S, Shapira MY: Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant; 2006 Dec;12(12):1295-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
  • The use of a mismatched allograft necessitates T cell depletion for prevention of uncontrolled graft-versus-host disease (GVHD), thus impairing a graft-versus-leukemia effect.
  • Data on donor lymphocyte infusion (DLI) after mismatched stem cell transplantation are lacking.
  • Death was frequent and usually related to the basic disease rather than to DLI complications.
  • Future developments using cell therapy with selective or targeted anticancer activity are warranted, with special attention to prophylactic treatment of T cell depleted mismatched allografts recipients.
  • [MeSH-major] Graft Enhancement, Immunologic. Leukemia, Myeloid / surgery. Lymphocyte Transfusion. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child, Preschool. Feasibility Studies. Female. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. HLA Antigens / immunology. Histocompatibility. Humans. Kaplan-Meier Estimate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukocyte Reduction Procedures. Lymphoma / surgery. Male. Middle Aged. Myelodysplastic Syndromes / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Remission Induction. Survival Analysis. Tissue Donors. Transplantation Conditioning. Tumor Burden

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162211.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


20. Cheng Y, Zhang Z, Slape C, Aplan PD: Cre-loxP-mediated recombination between the SIL and SCL genes leads to a block in T-cell development at the CD4- CD8- to CD4+ CD8+ transition. Neoplasia; 2007 Apr;9(4):315-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cre-loxP-mediated recombination between the SIL and SCL genes leads to a block in T-cell development at the CD4- CD8- to CD4+ CD8+ transition.
  • In the most common form of stem cell leukemia (SCL) gene rearrangement, an interstitial deletion of 82 kb brings SCL under the control of regulatory elements that normally govern expression of the ubiquitously expressed SCL interrupting locus (SIL) gene, which is located directly upstream of SCL.
  • To investigate the effect of this fusion in a mouse model, a bacterial artificial chromosome (BAC) clone containing both human SIL and SCL genes was isolated, and loxP sites were inserted into intron 1 of both the SIL and SCL genes, corresponding to the sites at which recombination occurs in human T-cell acute lymphocytic leukemia patients.
  • These transgenic mice were subsequently bred to Lck-Cre mice that express the Cre recombinase specifically in the thymus.
  • Aberrant SCL gene expression in the thymus was verified by reverse transcription-polymerase chain reaction.
  • These results demonstrate that conditional activation of SCL under control of SIL regulatory elements can impair normal T-cell development.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. CD4-Positive T-Lymphocytes / enzymology. CD8-Positive T-Lymphocytes / enzymology. Cell Differentiation / genetics. Extracellular Matrix Proteins / physiology. Gene Rearrangement, T-Lymphocyte / genetics. Integrases / genetics. Intracellular Signaling Peptides and Proteins / genetics. Protein-Lysine 6-Oxidase / physiology. Proto-Oncogene Proteins / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6861-5 [1495975.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6382-7 [11522630.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3931-8 [12010791.001]
  • [Cites] Biochim Biophys Acta. 2003 Jan 27;1625(2):207-13 [12531481.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1303-10 [1402676.001]
  • [Cites] J Immunol. 1993 May 15;150(10):4244-52 [8387091.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):205-9 [7824274.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):432-4 [7830794.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):376-85 [7795643.001]
  • [Cites] EMBO J. 1996 Mar 1;15(5):1021-7 [8605871.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2649-58 [8639880.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5160-6 [8895560.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5113-9 [8912842.001]
  • [Cites] EMBO J. 1997 May 1;16(9):2408-19 [9171354.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):473-9 [9472016.001]
  • [Cites] Blood. 1999 May 1;93(9):2760-70 [10216069.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):5025-35 [10373552.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):e36 [15731329.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5039-43 [2740341.001]
  • [Cites] EMBO J. 1990 Oct;9(10):3343-51 [2209547.001]
  • [Cites] J Exp Med. 1990 Nov 1;172(5):1403-8 [2230650.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6426-35 [2247063.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1426-9 [2255914.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5462-9 [1922059.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1327-33 [1311214.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):138-44 [11248806.001]
  • (PMID = 17460775.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC010379-06
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Extracellular Matrix Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / STIL protein, human; 135471-20-4 / TAL1 protein, human; 149137-54-2 / Lox protein, mouse; EC 1.4.3.13 / Protein-Lysine 6-Oxidase; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC1854848
  •  go-up   go-down


21. Au WY, Chan LC, Liang R, Kwong YL: Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone. Am J Hematol; 2006 Jun;81(6):471-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced


22. Yonekura K, Utsunomiya A, Takatsuka Y, Takeuchi S, Tashiro Y, Kanzaki T, Kanekura T: Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant; 2008 Jun;41(12):1029-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has proven effective in adult T-cell leukemia/lymphoma (ATL) patients.
  • Of these, 18 had acute-, 2 had lymphoma- and 1 had chronic-type ATL; at allo-HSCT, seven patients were in CR, one was in PR, five had stable disease (SD) and eight had progressive disease (PD).
  • Disease state after allo-HSCT was CR in 14, PR in 3, SD in 1 and PD in 3 patients.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Cohort Studies. Disease-Free Survival. Drug Administration Schedule. Female. Graft vs Host Disease / drug therapy. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Recurrence. Retrospective Studies. Skin Diseases / pathology. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332910.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


23. Advani A, Jin T, Bolwell B, Copelan E, Sekeres M, Sobecks R, Sungren S, Yurch M, Kalaycio M: A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse. Leuk Lymphoma; 2009 Jul;50(7):1126-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse.
  • The outcome of patients with acute lymphoblastic leukemia (ALL) in first relapse is poor.
  • For all patients, a scoring system of 0-3 was developed with 1 point for each of the following: age at diagnosis >or=45 years, lactate dehydrogenase (LDH) at the time of relapse >or=1.5 times upper limits of normal (ULN), not proceeding to allogeneic bone marrow transplant (BMT).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Medical Oncology / methods. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Prognosis. Recurrence. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19557633.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


24. Hoshino T, Tahara K, Miyawaki K, Hatsumi N, Takada S, Miyawaki S, Sakura T: [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib]. Rinsho Ketsueki; 2010 Mar;51(3):181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
  • We retrospectively analyzed the clinical outcome of dasatinib in 7 patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to imatinib.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Thiazoles / administration & dosage


25. Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo T, Nishio M, Sato N, Tanaka J, Hashino S, Koike T, Asaka M, Imamura M: Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. Int J Hematol; 2010 Mar;91(2):310-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.
  • Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy.
  • If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option.
  • Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks.
  • Both the 3-year OS and RFS rates were 81% in the conventional stem cell transplantation (CST) group.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Cytogenetics. Disease-Free Survival. Female. Graft vs Host Disease / mortality. Humans. Karyotyping. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Analysis. Young Adult


26. Akiyama M, Kobayashi N, Fujisawa K, Eto Y: Disseminated Varicella-Zoster virus infection in a girl with T-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Jun 15;48(7):716
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated Varicella-Zoster virus infection in a girl with T-lineage acute lymphoblastic leukemia.
  • [MeSH-major] Herpes Zoster / complications. Leukemia-Lymphoma, Adult T-Cell / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2005 Aug;45(2):191-4 [15880424.001]
  • (PMID = 16607647.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / gamma-Globulins
  •  go-up   go-down


27. Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R: Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol; 2006 Oct;77(4):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
  • The treatment of relapsed adult acute lymphoblastic leukaemia (ALL) is frequently unsuccessful with current chemotherapy regimens, and often there is an overexpression of multidrug resistance (MDR)-related proteins.
  • Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that liposomal-encapsulated DNR (Daunoxome-DNX) is more toxic than DNR against ALL cell lines.
  • Twenty pts (80%) achieved a complete remission (CR) and two (8%) entered a partial remission (PR) for an overall response (OR) rate of 88% (22/25), with a tolerable toxicity and without significant cardiotoxicity.
  • Before the start of DNX therapy, 18/25 (72%) cases overexpressed at least one MDR-related protein compared with 9/25 (36%) cases with MDR overexpression at diagnosis (P = 0.01).
  • Taking into account the small number of cases, the response rate was not affected by MDR expression and the in vitro results also showed a higher uptake and apoptotic cell death by DNX compared with DNR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multidrug Resistance-Associated Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856922.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Liposomes; 0 / Multidrug Resistance-Associated Proteins; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


28. Olwill SA, McGlynn H, Gilmore WS, Alexander HD: Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Thromb Res; 2005;115(1-2):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines.
  • INTRODUCTION: Acute promyelocytic leukaemia (APL) (M3) is associated with both a characteristic t(15;17) and severe bleeding diathesis caused by disseminated intravascular coagulation (DIC) and/or hyperfibrinolysis.
  • MATERIALS AND METHODS: This study examined the level of annexin II cell surface and mRNA expression in a range of acute myeloid leukaemia (AML) cell lines.
  • The evidence that annexin II levels are higher in APL would lend support to the hypothesis that the bleeding disorder seen in APL is caused by hyperfibrinolysis.
  • RESULTS: Cell surface annexin II was found to be expressed at higher levels on NB4 (promyelocytic) cells than on either KG1a (early myeloid) or HL60 (myelocytic) cells.
  • MM6 cells showed a threefold increase in annexin II mRNA compared to any of the other cell lines.
  • Further investigations are required to identify the significance of annexin II expression and regulation in leukaemia.
  • [MeSH-major] Annexin A2 / genetics. Gene Expression Regulation, Neoplastic. Leukemia, Myeloid / metabolism. Leukemia, Promyelocytic, Acute / complications. RNA, Messenger / analysis
  • [MeSH-minor] Cell Line, Tumor. Fibrinolysis. Hemorrhage / etiology. Humans. Membrane Proteins

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567461.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANXA2 protein, human; 0 / Annexin A2; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


29. Nezu M, Tomonaga T, Sakai C, Ishii A, Itoga S, Nishimura M, Matsuo Y, Tagawa M, Nomura F: Expression of the fetal-oncogenic fibroblast growth factor-8/17/18 subfamily in human hematopoietic tumors. Biochem Biophys Res Commun; 2005 Sep 30;335(3):843-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To elucidate whether these FGFs (FGF-8, -9, -10, -11, -12, -13, -14, -16, -17, -18, -19, -20, and -21) are expressed in leukemic cells, we performed RT-PCR analyses using 28 cell lines.
  • Realtime quantitative-PCR analysis showed that FGF-8/-17 were aberrantly expressed in patients with acute leukemia.
  • Moreover, cell proliferation assays revealed the proliferation activity of FGF-17 on leukemic cells expressing its receptors.
  • [MeSH-minor] Base Sequence. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. DNA Primers. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095560.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down


30. Holler E: Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol; 2007 Jun;20(2):281-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment.
  • Graft-versus-host disease (GvHD) is the major cause of transplant-related mortality and morbidity.
  • As it is closely related to the major therapeutic principle, graft-versus-leukaemia (GvL) effect, risk assessment has to balance both risks depending on the pre-transplant status.
  • While the majority of approaches aiming at T-cell depletion show efficacy in reducing acute and chronic GvHD and transplant-related mortality, T-cell depletion also affects graft-versus-leukaemia effects and thus results in a higher relapse rate.
  • Thus, standard prophylaxis relying on calcineurin inhibitors frequently results in at least equivalent or even superior long-term disease-free survival, and the risk of relapse has to be considered when selecting regimens for prevention of GvHD.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Acute Disease. Adrenal Cortex Hormones / therapeutic use. Calcineurin Inhibitors. Chronic Disease / drug therapy. Cyclosporine / therapeutic use. Graft vs Leukemia Effect / drug effects. Humans. Immunosuppressive Agents / therapeutic use. Methotrexate / therapeutic use. Methylprednisolone / therapeutic use. Mycophenolic Acid / analogs & derivatives. Mycophenolic Acid / therapeutic use. Risk Assessment. T-Lymphocytes / physiology. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448962.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; WM0HAQ4WNM / Tacrolimus; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 95
  •  go-up   go-down


31. Sweetenham JW: Lymphoblastic lymphoma in adults. Curr Hematol Malig Rep; 2006 Dec;1(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma in adults.
  • Understanding of the pathogenesis and biology of precursor T-cell and B-cell neoplasms has advanced significantly with the description of gene expression profiling studies, especially in T-cell disease.
  • Optimal treatment strategies for adult lymphoblastic lymphoma are uncertain, although current evidence supports the use of regimens similar to those used in acute lymphoblastic leukemia, with intensive induction therapy, central nervous system prophylaxis, and prolonged consolidation maintenance therapy.
  • Current studies do not demonstrate a benefit from stem cell transplantation in first remission, although this approach is probably beneficial in relapsed disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. B-Lymphocytes / pathology. Child. Combined Modality Therapy. Gene Expression Regulation, Neoplastic. Gene Rearrangement. Hematopoietic Stem Cell Transplantation. Humans. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Remission Induction. Salvage Therapy. T-Lymphocytes / pathology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):291-6 [7866277.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):268-74 [14983942.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):319-24 [686542.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):101-8 [10613454.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Br J Haematol. 1989 Sep;73(1):82-7 [2803982.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):183-90 [2954631.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2347-57 [6895347.001]
  • [Cites] Ann Oncol. 1995 May;6(5):445-51 [7545428.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1358-65 [8021726.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):57-67 [3510283.001]
  • [Cites] Blood. 2004 Jan 15;103(2):442-50 [14504110.001]
  • [Cites] J Clin Invest. 1985 Jul;76(1):248-53 [2410458.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Ann Oncol. 1990;1(2):141-6 [2078494.001]
  • [Cites] Mol Diagn. 1996 Jun;1(2):139-151 [10330209.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] J Pathol. 1999 Jul;188(3):267-70 [10419594.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):644-6 [1548528.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):619-25 [9681075.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] Bone Marrow Transplant. 1992 Jul;10(1):33-8 [1515876.001]
  • [Cites] Cancer. 2002 May 15;94(10):2738-44 [12173345.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):423-9 [14976526.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):577-82 [9031089.001]
  • [Cites] Cancer. 1979 Dec;44(6):1990-9 [389403.001]
  • [Cites] Blood. 1981 Apr;57(4):679-84 [6970598.001]
  • (PMID = 20425319.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


32. Berman JN, Look AT: Targeting transcription factors in acute leukemia in children. Curr Drug Targets; 2007 Jun;8(6):727-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting transcription factors in acute leukemia in children.
  • Transcription factors play essential roles in controlling normal blood development and their alteration leads to abnormalities in cell proliferation, differentiation and survival.
  • In many childhood acute leukemias, transcription factors are altered through chromosomal translocations that change their functional properties resulting in repressed activity or inappropriate activation.
  • The development of therapies that specifically target these molecular abnormalities holds promise for improving the outcome in diseases that remain challenging to treat, such as childhood T-cell acute lymphoblastic leukemia and acute myeloid leukemia, with improved toxicity profiles.
  • All trans-retinoic acid and arsenic trioxide have already demonstrated efficacy in acute promyelocytic leukemia in both adults and children.
  • Newer agents, such as histone deacetylase inhibitors, drugs targeting the NOTCH pathway, and short interfering RNAs have shown encouraging results in pre-clinical studies and are likely to enter the clinical arena in the near future.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Delivery Systems. Leukemia / drug therapy. Transcription Factors / drug effects
  • [MeSH-minor] Acute Disease. Arsenicals / pharmacology. Arsenicals / therapeutic use. Child. DNA Methylation / drug effects. Histone Deacetylase Inhibitors. Humans. Oxides / pharmacology. Oxides / therapeutic use. Tretinoin / pharmacology. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17584028.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Histone Deacetylase Inhibitors; 0 / Oxides; 0 / Transcription Factors; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 113
  •  go-up   go-down


33. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA: The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer; 2007 Dec;49(7):928-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PPTP has established panels of childhood cancer xenografts and cell lines to be used for in vivo and in vitro testing.
  • These include panels for Wilms tumor, sarcomas (rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma), neuroblastoma, brain tumors (glioblastoma, ependymoma, and medulloblastoma), rhabdoid tumors (CNS and renal), and acute lymphoblastic leukemia (ALL).
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Disease Models, Animal. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Injections, Intraperitoneal. Mice. Mice, Inbred BALB C. Mice, Inbred NOD. Mice, Nude. Mice, SCID. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17066459.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


34. Zhang X, Huang H, Xu Z, Zhan R: 2-Methoxyestradiol blocks cell-cycle progression at the G2/M phase and induces apoptosis in human acute T lymphoblastic leukemia CEM cells. Acta Biochim Biophys Sin (Shanghai); 2010 Sep;42(9):615-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Methoxyestradiol blocks cell-cycle progression at the G2/M phase and induces apoptosis in human acute T lymphoblastic leukemia CEM cells.
  • The current study sought to determine the mechanism of anti-cancer activity of 2-ME2 in human acute T lymphoblastic leukemia CEM cells.
  • Exposure to 2-ME2 led to G(2)/M phase cell-cycle arrest, which preceded apoptosis characterized by the appearance of a sub-G(1) cell population.
  • Our findings revealed that 2-ME2 might be a potent natural candidate for chemotherapeutic treatment of human acute T lymphoblastic leukemia when the precise effects of 2-ME2 were investigated further in other T leukemia cell lines and in primary T-cell leukemias.
  • [MeSH-major] Apoptosis / drug effects. Cell Cycle / drug effects. Estradiol / analogs & derivatives
  • [MeSH-minor] Apoptosis Regulatory Proteins / genetics. Apoptosis Regulatory Proteins / metabolism. Blotting, Western. Cell Division / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. DNA Fragmentation / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. G2 Phase / drug effects. Gene Expression Regulation, Leukemic / drug effects. Humans. Membrane Potential, Mitochondrial / drug effects. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Tubulin Modulators / pharmacology. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20732853.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tubulin Modulators; 0 / Tumor Suppressor Protein p53; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol
  •  go-up   go-down


35. Souroullas GP, Salmon JM, Sablitzky F, Curtis DJ, Goodell MA: Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival. Cell Stem Cell; 2009 Feb 6;4(2):180-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Scl and Lyl1 encode two related basic-helix-loop-helix transcription factors implicated in T cell acute lymphoblastic leukemia.
  • Previous studies showed that Scl is essential for embryonic and adult erythropoiesis, while Lyl1 is important for B cell development.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2001 Dec;1(3):193-9 [11905828.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):547-51 [12540851.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] Blood. 2004 May 1;103(9):3342-8 [14726374.001]
  • [Cites] EMBO J. 1994 Oct 17;13(20):4831-9 [7957052.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):143-9 [7969446.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):432-4 [7830794.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7075-9 [7624372.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2394-401 [8628307.001]
  • [Cites] Blood. 1996 May 15;87(10):4025-39 [8639758.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Development. 1998 Jul;125(13):2349-58 [9609818.001]
  • [Cites] J Exp Med. 1998 Aug 3;188(3):439-50 [9687522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11897-902 [9751762.001]
  • [Cites] Development. 1999 Oct;126(20):4603-15 [10498694.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4678-86 [16514064.001]
  • [Cites] Gene Expr Patterns. 2007 Jan;7(3):215-26 [17112790.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1908-16 [17053063.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3573-81 [17644741.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17692-7 [17962413.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3005-14 [18184866.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1068-77 [18523151.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):578-91 [18371395.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1016-26 [18927439.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):97-8 [11248796.001]
  • (PMID = 19200805.001).
  • [ISSN] 1875-9777
  • [Journal-full-title] Cell stem cell
  • [ISO-abbreviation] Cell Stem Cell
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL096360; United States / NHLBI NIH HHS / HL / HL 08100; United States / NIDDK NIH HHS / DK / DK058192-09; United States / NIDDK NIH HHS / DK / R01 DK058192-09; United States / NIBIB NIH HHS / EB / R01 EB005173; United States / NIBIB NIH HHS / EB / EB 005173; United States / NIBIB NIH HHS / EB / R01 EB005173-04; United States / NIDDK NIH HHS / DK / R01 DK058192; United States / NHLBI NIH HHS / HL / U54 HL081007-04; United States / NIBIB NIH HHS / EB / EB005173-04; United States / NIDDK NIH HHS / DK / DK 58192; United States / NHLBI NIH HHS / HL / HL081007-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Lyl1 protein, mouse; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse
  • [Other-IDs] NLM/ NIHMS100258; NLM/ PMC2672304
  •  go-up   go-down


36. Advani AS, Lim K, Gibson S, Shadman M, Jin T, Copelan E, Kalaycio M, Sekeres MA, Sobecks R, Hsi E: OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma; 2010 Apr;51(4):606-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia.
  • OCT-2 and its co-activator, BOB.1, are B-cell associated transcription factors expressed in a subset of patients with acute myeloid leukemia (AML).
  • OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Octamer Transcription Factor-2 / metabolism. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141429.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Octamer Transcription Factor-2; 0 / POU2AF1 protein, human; 0 / POU2F2 protein, human; 0 / Trans-Activators
  •  go-up   go-down


37. Cines DB, Liebman H, Stasi R: Pathobiology of secondary immune thrombocytopenia. Semin Hematol; 2009 Jan;46(1 Suppl 2):S2-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary immune thrombocytopenic purpura (ITP) remains a diagnosis of exclusion both from nonimmune causes of thrombocytopenia and immune thrombocytopenia that develops in the context of other disorders (secondary immune thrombocytopenia).
  • The pathobiology, natural history, and response to therapy of the diverse causes of secondary ITP differ from each other and from primary ITP, so accurate diagnosis is essential.
  • Immune thrombocytopenia can be secondary to medications or to a concurrent disease, such as an autoimmune condition (eg, systemic lupus erythematosus [SLE], antiphospholipid antibody syndrome [APS], immune thyroid disease, or Evans syndrome), a lymphoproliferative disease (eg, chronic lymphocytic leukemia or large granular T-lymphocyte lymphocytic leukemia), or chronic infection, eg, with Helicobacter pylori, human immunodeficiency virus (HIV), or hepatitis C virus (HCV).
  • This thrombocytopenia may be caused by cross-reacting antibodies and closely mimics acute ITP of childhood.
  • Proper diagnosis and treatment of the underlying disorder, where necessary, play an important role in patient management.

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1975 Aug;64(2):180-91 [1171614.001]
  • [Cites] Arthritis Rheum. 1981 Aug;24(8):1024-36 [7284049.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):714-7 [6178333.001]
  • [Cites] Q J Med. 1991 Jul;80(291):605-12 [1946940.001]
  • [Cites] J Clin Invest. 1992 Feb;89(2):356-64 [1737832.001]
  • [Cites] Blood. 1992 Jul 1;80(1):162-9 [1611083.001]
  • [Cites] J Rheumatol. 1992 May;19(5):803-6 [1613714.001]
  • [Cites] N Engl J Med. 1992 Dec 17;327(25):1779-84 [1435932.001]
  • [Cites] Haematologica. 1992 Sep-Oct;77(5):398-401 [1483588.001]
  • [Cites] Acta Paediatr. 1993 Mar;82(3):267-70 [8495082.001]
  • [Cites] Lancet. 1993 Nov 20;342(8882):1274-5 [7694021.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2263-7 [7892259.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1719-26 [7535585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3234-8 [7536928.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1347-9 [7539157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5292-6 [7777500.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3444-51 [7780132.001]
  • [Cites] Cell. 1995 Jun 16;81(6):935-46 [7540117.001]
  • [Cites] FEBS Lett. 1995 Aug 14;370(1-2):63-8 [7544303.001]
  • [Cites] FEBS Lett. 1995 Dec 27;377(3):497-501 [8549784.001]
  • [Cites] Blood. 1996 May 15;87(10):4068-71 [8639762.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):704-6 [8652398.001]
  • [Cites] Pediatr Infect Dis J. 1996 Jan;15(1):88-90 [8684885.001]
  • [Cites] Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S39-43 [8730475.001]
  • [Cites] Blood. 1996 Jul 1;88(1):3-40 [8704187.001]
  • [Cites] Lancet. 1996 Sep 14;348(9029):719-23 [8806292.001]
  • [Cites] Blood. 2004 Jan 15;103(2):500-6 [12969975.001]
  • [Cites] Am J Med. 1996 Nov;101(5):502-7 [8948273.001]
  • [Cites] Blood. 1997 Jan 15;89(2):483-92 [9002950.001]
  • [Cites] Thromb Haemost. 1997 May;77(5):808-14 [9184382.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):127-31 [9252085.001]
  • [Cites] Br J Haematol. 1997 Aug;98(2):336-41 [9266930.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1787-98 [9292511.001]
  • [Cites] Br J Haematol. 1997 Sep;98(4):873-9 [9326182.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1479-95 [9473211.001]
  • [Cites] Gut. 1998 Mar;42(3):338-43 [9577338.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):656-8 [9674737.001]
  • [Cites] Haematologica. 1998 Jul;83(7):669-70 [9718878.001]
  • [Cites] Scand J Infect Dis. 1998;30(2):115-8 [9730294.001]
  • [Cites] Clin Exp Immunol. 1998 Sep;113(3):373-8 [9737665.001]
  • [Cites] Lancet. 1998 Sep 12;352(9131):878 [9742983.001]
  • [Cites] Ann Intern Med. 1998 Dec 1;129(11):886-90 [9867731.001]
  • [Cites] Blood. 2003 Aug 1;102(3):887-95 [12676790.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1670-7 [12738668.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1123-4 [12937414.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):91-6 [14675413.001]
  • [Cites] Blood. 2004 Feb 1;103(3):890-6 [12920031.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1364-9 [14576051.001]
  • [Cites] Arch Intern Med. 2004 Feb 23;164(4):361-9 [14980986.001]
  • [Cites] Ann Intern Med. 2004 May 4;140(9):766-7 [15126268.001]
  • [Cites] J Thromb Haemost. 2004 Jun;2(6):985-92 [15140135.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):434-40 [14963696.001]
  • [Cites] Indian J Pediatr. 2004 Jun;71(6):505-7 [15226559.001]
  • [Cites] J Clin Invest. 1966 May;45(5):645-57 [5327481.001]
  • [Cites] N Engl J Med. 1974 Jan 31;290(5):249-51 [4855568.001]
  • [Cites] N Engl J Med. 1974 May 2;290(18):989-93 [4594526.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2346-53 [16304054.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):230-9 [16616070.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):427-31 [16480433.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1212-8 [16380230.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):391-6 [16680753.001]
  • [Cites] J Invasive Cardiol. 2006 Jun;18(6):E173-4 [16775895.001]
  • [Cites] Clin Exp Immunol. 2006 Jul;145(1):71-80 [16792676.001]
  • [Cites] Blood. 2006 Aug 1;108(3):922-7 [16861345.001]
  • [Cites] Br J Haematol. 1982 Jul;51(3):445-50 [7104228.001]
  • [Cites] Arch Neurol. 1983 Sep;40(9):552-4 [6615286.001]
  • [Cites] J Pediatr. 1983 Dec;103(6):877-81 [6644422.001]
  • [Cites] Am J Hematol. 1983 Dec;15(4):381-90 [6606357.001]
  • [Cites] J Infect. 1984 May;8(3):274-6 [6736670.001]
  • [Cites] N Engl J Med. 1984 Sep 6;311(10):635-9 [6540841.001]
  • [Cites] Blood. 1985 Mar;65(3):584-8 [4038614.001]
  • [Cites] Ann Intern Med. 1986 Jan;104(1):47-50 [3000249.001]
  • [Cites] J Thromb Haemost. 2007 Jul;5(7):1538-44 [17470198.001]
  • [Cites] N Engl J Med. 2007 Aug 9;357(6):580-7 [17687133.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2924-30 [17548576.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):419-26 [17934346.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):511-4 [17934360.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):557-73 [17934365.001]
  • [Cites] Blood. 2007 Dec 1;110(12):3833-41 [17652264.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2227-36 [18046027.001]
  • [Cites] Thyroid. 2007 Nov;17(11):1137-42 [17887931.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4 Suppl 5):S24-34 [18096469.001]
  • [Cites] Eur J Haematol Suppl. 2008 Feb;(69):3-8 [18211567.001]
  • [Cites] Blood. 2008 Feb 1;111(3):981-6 [18223171.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):257-66 [18256550.001]
  • [Cites] Leuk Res. 2008 May;32(5):823-7 [17915315.001]
  • [Cites] Respirology. 2008 Mar;13 Suppl 1:S10-3 [18366521.001]
  • [Cites] Virol J. 2008;5:47 [18371229.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):231-7 [18628092.001]
  • [Cites] J Clin Invest. 2008 Aug;118(8):2939-49 [18654664.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1147-50 [18375792.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1078-84 [18519809.001]
  • [Cites] Hematology. 2008 Jun;13(3):181-2 [18702877.001]
  • [Cites] J Thromb Haemost. 2008 Aug;6(8):1304-12 [18489711.001]
  • [Cites] Circulation. 1997 Mar 4;95(5):1242-6 [9054855.001]
  • [Cites] Blood. 2000 Feb 1;95(3):769-75 [10648384.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):397-404 [10674912.001]
  • [Cites] Semin Hematol. 2000 Jul;37(3):239-48 [10942218.001]
  • [Cites] Stem Cells. 1996;14 Suppl 1:188-93 [11012220.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1404-6 [11100362.001]
  • [Cites] Can J Gastroenterol. 2000 Nov;14 Suppl D:60D-66D [11110614.001]
  • [Cites] Curr Gastroenterol Rep. 2001 Feb;3(1):71-8 [11177698.001]
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1286-92 [11320387.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):590-5 [11380442.001]
  • [Cites] Br J Haematol. 1986 Jul;63(3):509-16 [3089270.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] N Engl J Med. 1987 Mar 5;316(10):581-9 [3807952.001]
  • [Cites] J Clin Invest. 1987 Jul;80(1):33-40 [3597777.001]
  • [Cites] Br J Haematol. 1987 Jun;66(2):251-6 [3606961.001]
  • [Cites] Br J Haematol. 1987 Jul;66(3):337-40 [3620353.001]
  • [Cites] Eur J Haematol. 1988 May;40(5):437-41 [3378597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(24):9763-7 [3200854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5595-9 [2748605.001]
  • [Cites] Am J Pathol. 1989 Jun;134(6):1295-303 [2757119.001]
  • [Cites] J Rheumatol. 1989 Oct;16(10):1359-61 [2810261.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Feb;70(2):491-6 [2298861.001]
  • [Cites] Nature. 1990 Mar 29;344(6265):444-7 [2320112.001]
  • [Cites] Blood. 1990 May 15;75(10):1920-3 [2337668.001]
  • [Cites] Blood. 1991 Feb 1;77(3):481-5 [1991165.001]
  • [Cites] Blood. 1991 Jun 15;77(12):2668-76 [1710517.001]
  • [Cites] Arthritis Rheum. 2006 Aug;54(8):2558-67 [16868978.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Eur J Haematol. 2006 Dec;77(6):513-7 [17042765.001]
  • [Cites] J Thromb Haemost. 2007 Feb;5(2):369-77 [17096706.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1024-32 [8111044.001]
  • [Cites] J Lab Clin Med. 1994 Mar;123(3):415-20 [8133154.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Jan-Feb;9(1):99-104 [8155875.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Thromb Haemost. 1994 May;71(5):571-5 [8091382.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):232-6 [7957808.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4203-8 [7994034.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1252-4 [11493478.001]
  • [Cites] Circulation. 2001 Aug 21;104(8):870-5 [11514371.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1760-4 [11535509.001]
  • [Cites] Cell. 2001 Sep 7;106(5):551-61 [11551503.001]
  • [Cites] Ann Intern Med. 2001 Oct 2;135(7):502-6 [11578153.001]
  • [Cites] Arch Dis Child. 2001 Mar;84(3):227-9 [11207170.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2293-300 [11588022.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2442-7 [11588041.001]
  • [Cites] Rev Clin Exp Hematol. 2001 Sep;5(3):166-200; discussion 311-2 [11703814.001]
  • [Cites] Am J Hematol. 2001 Nov;68(3):215 [11754406.001]
  • [Cites] JAMA. 2002 Jan 23-30;287(4):505-9 [11798374.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):75-83 [11824975.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):132-4 [11835350.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2054-9 [11877279.001]
  • [Cites] N Engl J Med. 2002 Mar 28;346(13):995-1008 [11919310.001]
  • [Cites] Blood. 2002 Jul 1;100(1):344-6 [12070047.001]
  • [Cites] Chest. 2002 Jul;122(1):37-42 [12114336.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1388-98 [12149222.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2040-5 [12190174.001]
  • [Cites] Helicobacter. 2002;7 Suppl 1:17-23 [12197905.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2148-59 [12209520.001]
  • [Cites] Eur J Haematol. 2002 Nov-Dec;69(5-6):303-8 [12460235.001]
  • [Cites] Br J Clin Pharmacol. 2003 Jan;55(1):107-11 [12534647.001]
  • [Cites] Pediatr Infect Dis J. 2003 Feb;22(2):119-22 [12586974.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):574-96 [12588344.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):124-33 [12655301.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1267-76 [12774004.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1846-54 [12806618.001]
  • [Cites] Gut. 1999 Mar;44(3):336-41 [10026317.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):220-9 [10050701.001]
  • [Cites] Thromb Haemost. 1999 Mar;81(3):436-41 [10102474.001]
  • [Cites] Gut. 1999 May;44(5):754-8 [10205219.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4054-62 [15315970.001]
  • [Cites] Drug Saf. 2004;27(15):1243-52 [15588119.001]
  • [Cites] Blood. 2005 Jan 1;105(1):215-8 [15191945.001]
  • [Cites] Blood. 2005 Jan 1;105(1):131-8 [15304392.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2004 Dec;12(12):734-6 [15619340.001]
  • [Cites] Br J Haematol. 2005 Feb;128(3):366-72 [15667539.001]
  • [Cites] Chest. 2005 Feb;127(2 Suppl):53S-59S [15706031.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2443-8 [15542578.001]
  • [Cites] Am J Med. 2005 Apr;118(4):414-9 [15808140.001]
  • [Cites] Vaccine. 2005 Jun 10;23(30):3876-86 [15917108.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):818-24 [15953010.001]
  • [Cites] Am J Hematol. 2005 Jul;79(3):175-9 [15981229.001]
  • [Cites] Blood. 2005 Jul 15;106(2):572-6 [15774614.001]
  • [Cites] Platelets. 2005 Aug;16(5):307-11 [16011982.001]
  • [Cites] Hematology. 2005 Apr;10(2):101-5 [16019455.001]
  • [Cites] Eur J Haematol. 2005 Nov;75(5):417-23 [16191092.001]
  • (PMID = 19245930.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL040387-16; United States / NHLBI NIH HHS / HL / P01 HL040387; United States / NHLBI NIH HHS / HL / P01 HL040387-16
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 185
  • [Other-IDs] NLM/ NIHMS99872; NLM/ PMC2682438
  •  go-up   go-down


38. Turano M, Napolitano G, Dulac C, Majello B, Bensaude O, Lania L: Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation. J Cell Physiol; 2006 Mar;206(3):603-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation.
  • To determine the causative role of HEXIM1 during cell differentiation we analyzed the biochemical and functional consequences of HEXIM1 protein levels in several in vitro differentiation systems.
  • These findings highlight a crucial role of HEXIM1 protein during cell differentiation.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Erythroblastic, Acute / genetics. Neuroblastoma / genetics. Positive Transcriptional Elongation Factor B / metabolism. RNA-Binding Proteins / genetics
  • [MeSH-minor] Acetamides / pharmacology. Animals. Cell Differentiation. Cell Line, Tumor. Dimethyl Sulfoxide / pharmacology. Humans. Mice. Transcription, Genetic / drug effects. Tretinoin / pharmacology. U937 Cells

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16222702.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / HEXIM1 protein, human; 0 / RNA-Binding Proteins; 5688UTC01R / Tretinoin; EC 2.7.11.- / Positive Transcriptional Elongation Factor B; LA133J59VU / hexamethylene bisacetamide; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


39. Serwold T, Hochedlinger K, Swindle J, Hedgpeth J, Jaenisch R, Weissman IL: T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell. Proc Natl Acad Sci U S A; 2010 Nov 2;107(44):18939-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell.
  • Pluripotent stem cell lines can now be generated from an individual's own cells, facilitating the generation of immunologically acceptable stem cell-based therapeutics.
  • Many cell types can undergo nuclear reprogramming, leading to the question of whether the identity of the reprogrammed cell of origin has a biological consequence.
  • Peripheral blood, containing a mixture of T, B, NK, and myeloid cell types, represents one potential source of reprogrammable cells.
  • In this study, we describe the unique case of mice derived from a reprogrammed T cell.
  • These mice have prerearranged T-cell receptor (TCR) genes in all cells.
  • Surprisingly, ≈50% of mice with prerearranged TCR genes develop spontaneous T cell lymphomas, which originate in the thymus.
  • The lymphomas arise from developing T cells, and contain activated Notch1, similar to most human and mouse T-cell acute lymphoblastic lymphomas.
  • Furthermore, inhibitors of multiple branches of TCR signaling suppress lymphoma growth, implicating TCR signaling as an essential component in lymphoma proliferation.
  • The lymphomagenesis in mice derived from a reprogrammed T cell demonstrates the deleterious consequences of misregulation of the TCR rearrangement and signaling pathways and illustrates one case of cellular reprogramming where the identity of the cell of origin has profound consequences.
  • [MeSH-major] Adult Stem Cells / metabolism. Cell Dedifferentiation. Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Signal Transduction. T-Lymphocytes / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Knockout. Receptor, Notch1 / genetics. Receptor, Notch1 / immunology. Receptor, Notch1 / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Feb 28;415(6875):1035-8 [11875572.001]
  • [Cites] Annu Rev Immunol. 2002;20:761-94 [11861617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12889-94 [12235366.001]
  • [Cites] Genesis. 2002 Nov;34(3):203-7 [12395385.001]
  • [Cites] Nature. 2003 May 22;423(6938):435-9 [12761548.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1113-20 [12916862.001]
  • [Cites] Curr Opin Immunol. 2004 Jun;16(3):360-6 [15134786.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Int J Cancer. 1977 Mar 15;19(3):403-13 [300367.001]
  • [Cites] Cell. 1979 May;17(1):65-75 [222476.001]
  • [Cites] Nature. 1985 Jan 24-30;313(6000):318-20 [3918270.001]
  • [Cites] Cell. 1987 Apr 10;49(1):143-51 [2435413.001]
  • [Cites] J Mol Cell Immunol. 1987;3(4):227-42 [2855408.001]
  • [Cites] Nature. 1990 Feb 22;343(6260):762-4 [2154701.001]
  • [Cites] Nature. 1992 Jun 25;357(6380):695-7 [1377362.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2089-99 [8668334.001]
  • [Cites] Mol Med. 1997 Jan;3(1):72-81 [9132282.001]
  • [Cites] Genes Dev. 1997 Apr 1;11(7):824-34 [9106655.001]
  • [Cites] Eur J Immunol. 1997 Nov;27(11):3039-48 [9394835.001]
  • [Cites] Blood. 1998 Feb 1;91(3):1001-7 [9446662.001]
  • [Cites] Semin Immunol. 1999 Aug;11(4):227-37 [10441209.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4518-23 [15758071.001]
  • [Cites] Cloning Stem Cells. 2005;7(2):119-25 [15971985.001]
  • [Cites] JAMA. 2005 Sep 21;294(11):1359-66 [16174694.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nat Med. 2007 Jun;13(6):736-41 [17515895.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):928-38 [17617584.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Annu Rev Pathol. 2008;3:587-613 [18039126.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):380-90 [18421304.001]
  • [Cites] Curr Biol. 2008 Jun 24;18(12):890-4 [18501604.001]
  • [Cites] Science. 2008 Aug 1;321(5889):699-702 [18276851.001]
  • [Cites] Nature. 2009 Oct 1;461(7264):649-3 [19718018.001]
  • [Cites] Cell Stem Cell. 2010 Jul 2;7(1):11-4 [20621043.001]
  • [Cites] Cell Stem Cell. 2010 Jul 2;7(1):15-9 [20621044.001]
  • [Cites] Cell Stem Cell. 2010 Jul 2;7(1):20-4 [20621045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7487-91 [11416218.001]
  • [Cites] J Exp Med. 2001 Jul 2;194(1):99-106 [11435476.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93 [11891328.001]
  • (PMID = 20956329.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA086065; United States / NICHD NIH HHS / HD / R37 HD045022
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Notch1 protein, mouse; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta
  • [Other-IDs] NLM/ PMC2973852
  •  go-up   go-down


40. Hyde RK, Liu PP: RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1). J Cell Biochem; 2010 Aug 1;110(5):1039-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The core binding factor (CBF) acute myeloid leukemias (AMLs) are a prognostically distinct subgroup that includes patients with the inv(16) and t(8:21) chromosomal rearrangements.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Leukemia / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Acute Disease. Gene Expression Regulation, Leukemic. Humans. Leukemia, Myeloid / genetics. Models, Genetic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2010 Wiley-Liss, Inc.
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12822-7 [10536006.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1433-43 [20007544.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39579-88 [10984496.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):723-33 [11179217.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Nat Med. 2001 Apr;7(4):444-51 [11283671.001]
  • [Cites] Hematol J. 2001;2(3):206-9 [11920247.001]
  • [Cites] Nat Med. 2002 Jul;8(7):743-50 [12091906.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]
  • [Cites] Nat Struct Biol. 2002 Sep;9(9):674-9 [12172539.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):206-10 [12145660.001]
  • [Cites] Leukemia. 2003 Jan;17(1):9-16 [12529654.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jul;40(3):165-71 [15138996.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4255-62 [15156181.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4284-96 [15156185.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):624-30 [15146183.001]
  • [Cites] Ann Genet. 1973 Jun;16(2):109-12 [4125056.001]
  • [Cites] N Engl J Med. 1983 Sep 15;309(11):630-6 [6577285.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] Virology. 1993 May;194(1):314-31 [8386878.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3324-39 [8497254.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6859-63 [8341710.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1041-4 [8351518.001]
  • [Cites] Blood. 1995 May 1;85(9):2289-302 [7727763.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12359-63 [8901586.001]
  • [Cites] Cell. 1996 Nov 15;87(4):687-96 [8929537.001]
  • [Cites] Cell. 1996 Nov 15;87(4):697-708 [8929538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14059-64 [8943060.001]
  • [Cites] Nat Genet. 1997 Mar;15(3):303-6 [9054947.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5697-702 [9159135.001]
  • [Cites] Blood. 1998 May 1;91(9):3134-43 [9558367.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1890-6 [9586906.001]
  • [Cites] Oncogene. 1998 Nov 5;17(18):2287-93 [9811459.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7432-43 [9819429.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17186-91 [15569932.001]
  • [Cites] Nat Med. 2006 Aug;12(8):945-9 [16892037.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11214-8 [17145866.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):537-45 [17234761.001]
  • [Cites] EMBO J. 2007 Feb 21;26(4):1163-75 [17290219.001]
  • [Cites] Blood. 2007 May 15;109(10):4392-8 [17284535.001]
  • [Cites] Blood. 2007 Aug 1;110(3):799-805 [17412887.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):457-66 [17996649.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1392-401 [18511808.001]
  • [Cites] J Cell Sci. 2008 Dec 1;121(Pt 23):3981-90 [19001502.001]
  • [Cites] PLoS Genet. 2008 Nov;4(11):e1000275 [19043539.001]
  • [Cites] Blood. 2009 Jan 22;113(4):883-6 [19036704.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2853-8 [19202074.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3070-9 [19179469.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2849-50 [19779050.001]
  • [Cites] Blood. 2009 Oct 1;114(14):3001-7 [19666867.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8249-55 [19826043.001]
  • [Cites] Blood. 2009 Dec 17;114(26):5352-61 [19808697.001]
  • [Cites] Blood. 2000 Jul 15;96(2):655-63 [10887131.001]
  • (PMID = 20589720.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA HG000030-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human
  • [Other-IDs] NLM/ NIHMS360619; NLM/ PMC3298446
  •  go-up   go-down


41. Giebel S, Holowiecki J, Krawczyk-Kulis M, Jagoda K, Stella-Holowiecka B, Sadus-Wojciechowska M, Hellmann A, Dmoszynska A, Paluszewska M, Robak T, Konopka L, Seferynska I, Skotnicki AB, Kyrcz-Krzemien S: Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study. Leuk Lymphoma; 2009 Jun;50(6):1050-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455463.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


42. Kalra S, Paul MK, Balaram H, Mukhopadhyay AK: Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase--an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine in ALL cell line. J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May 1;850(1-2):7-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase--an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine in ALL cell line.
  • The thiopurine antimetabolite 6-mercaptopurine (6MP) is an important chemotherapeutic drug in the conventional treatment of childhood acute lymphoblastic leukemia (ALL).
  • This method was further validated using actively growing T-ALL cell line (Jurkat) to study the branched kinetics, wherein it was observed that treatment of 50 microM 6MP led to the generation of 12 microM TIMP and 0.8 microM 6TUA in 6 h at 37 degrees C.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antineoplastic Agents / therapeutic use. Chromatography, High Pressure Liquid / methods. Hypoxanthine Phosphoribosyltransferase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Xanthine Oxidase / metabolism
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Humans. Male. Reproducibility of Results. Sensitivity and Specificity. Spectrophotometry / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081813.001).
  • [ISSN] 1570-0232
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E7WED276I5 / 6-Mercaptopurine; EC 1.17.3.2 / Xanthine Oxidase; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


43. Zhang X, Inukai T, Hirose K, Akahane K, Nemoto A, Takahashi K, Sato H, Kagami K, Goi K, Sugita K, Nakazawa S: Induction of impaired membrane phospholipid asymmetry in mature erythrocytes after chemotherapy. Int J Hematol; 2005 Aug;82(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Senescent erythrocytes undergo a loss of phospholipid asymmetry in the plasma membrane and are removed from the circulation by phagocytosis.To examine the loss of phospholipid asymmetry in mature erythrocytes after chemotherapy, we monitored phosphatidylserine (PS)-exposing erythrocytes by using flow cytometry to detect annexin V-bound erythrocytes in the circulation of acute lymphoblastic leukemia patients after consolidation chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Erythrocyte Membrane / metabolism. Phospholipids / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Annexin A5 / metabolism. Bone Marrow / metabolism. Bone Marrow / pathology. Cell Aging / drug effects. Erythropoiesis / drug effects. Humans

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1982 Jun;139(2):321-8 [6953013.001]
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1143-56 [11753563.001]
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1197-206 [11753567.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3077-81 [9501218.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1683-92 [10477693.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1121-32 [9028933.001]
  • [Cites] J Clin Invest. 1985 Jun;75(6):1965-72 [4008648.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1873-80 [8781447.001]
  • [Cites] J Biol Chem. 1994 Jan 28;269(4):2399-404 [8300565.001]
  • [Cites] J Immunol. 1997 Apr 15;158(8):3690-7 [9103432.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1179-87 [8562945.001]
  • [Cites] J Cell Sci. 1998 Sep;111 ( Pt 18):2707-15 [9718364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(10):3311-5 [3458184.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2295-306 [11187921.001]
  • (PMID = 16146845.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antimetabolites, Antineoplastic; 0 / Phospholipids; 04079A1RDZ / Cytarabine
  •  go-up   go-down


44. Hagner N, Joerger M: Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res; 2010;2:293-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methotrexate is one of the earliest anticancer drugs and is extensively used in lymphoma, acute lymphoblastic leukemia, and osteosarcoma, among others.
  • Pemetrexed has been approved in combination with cisplatin as first-line treatment for advanced non-squamous-cell lung cancer, as a single agent for relapsed non-small-cell lung cancer after platinum-containing chemotherapy, and in combination with cisplatin for the treatment of pleural mesothelioma.
  • Pralatrexate has recently been approved in the United States for relapsed or refractory peripheral T-cell lymphoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1948 Jun 3;238(23):787-93 [18860765.001]
  • [Cites] Expert Rev Mol Med. 2009;11:e4 [19173758.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2038-45 [19307503.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4357-64 [19652067.001]
  • [Cites] Am J Health Syst Pharm. 2009 Nov 1;66(21):1890 [19850775.001]
  • [Cites] Oncology (Williston Park). 2009 Nov 30;23(13):1133-40 [20043461.001]
  • [Cites] Br J Cancer. 2010 Feb 16;102(4):673-7 [20125159.001]
  • [Cites] Clin Cancer Res. 2010 May 15;16(10):2872-80 [20460481.001]
  • [Cites] J Clin Oncol. 2010 Sep 20;28(27):e482-3; author reply e484 [20606096.001]
  • [Cites] Anticancer Drugs. 2010 Sep;21(8):777-84 [20634689.001]
  • [Cites] J Clin Oncol. 1984 Jan;2(1):2-7 [6583327.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;12(1):18-25 [6690069.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1649-55 [7602354.001]
  • [Cites] Biochemistry. 1994 Feb 8;33(5):1209-15 [8110752.001]
  • [Cites] Biochemistry. 1997 Apr 15;36(15):4399-411 [9109647.001]
  • [Cites] Cancer Invest. 1993;11(1):36-45 [8422595.001]
  • [Cites] Leukemia. 1996 Mar;10(3):439-46 [8642859.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):353-8 [14735176.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):13-7 [15655931.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4425-30 [15899835.001]
  • [Cites] Cell. 2005 Sep 9;122(5):789-801 [16143108.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8414-22 [16166320.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34 [16612649.001]
  • [Cites] Oncologist. 2006 Jun;11(6):694-703 [16794248.001]
  • [Cites] Cancer Invest. 2006 Apr-May;24(3):283-7 [16809156.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):71-80 [16842380.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):85-94 [16957834.001]
  • [Cites] Cell. 2006 Dec 1;127(5):917-28 [17129779.001]
  • [Cites] Cell Metab. 2007 Jan;5(1):5-6 [17189201.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):111-28 [17334909.001]
  • [Cites] Science. 1947 Dec 19;106(2764):619-21 [17831847.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):599-604 [18504579.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2046-51 [18528741.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):121-6 [9583724.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30189-98 [9804775.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):427-32 [10501918.001]
  • [Cites] Pharmacol Ther. 2000 Mar;85(3):191-205 [10739874.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):30855-63 [10899164.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(6):477-87 [11138461.001]
  • [Cites] Clin Pharmacokinet. 2000 Dec;39(6):429-43 [11192475.001]
  • [Cites] Oncology. 2001;60(2):134-40 [11244328.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):478-86 [11872339.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Biochem Pharmacol. 2002 Aug 15;64(4):669-75 [12167486.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3832-4 [12411325.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):8935-41 [12519783.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Aug;15(5):227-32 [12924450.001]
  • [Cites] Proc Soc Exp Biol Med. 1958 Feb;97(2):429-31 [13518295.001]
  • [Cites] N Engl J Med. 1958 Jul 10;259(2):66-74 [13566422.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1434-8 [1371715.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6):707-19 [1462168.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2071-6 [15341981.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):521-4 [1732038.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2424-31 [19671745.001]
  • [Cites] J Clin Invest. 1985 Oct;76(4):1323-9 [2414316.001]
  • [Cites] J Biol Chem. 1987 Oct 5;262(28):13520-6 [2443493.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):745-8 [301783.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5573-9 [3416310.001]
  • [Cites] Cancer Chemother Pharmacol. 1985;15(2):101-4 [3874719.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):978-82 [3971388.001]
  • [Cites] Biochem Biophys Res Commun. 1973 May 1;52(1):27-34 [4197190.001]
  • [Cites] Ann N Y Acad Sci. 1971 Nov 30;186:400-22 [5289428.001]
  • [Cites] J Biol Chem. 1968 Oct 10;243(19):5007-17 [5303004.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3190-5 [6204743.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] J Clin Oncol. 1984 Jan;2(1):8-15 [6699660.001]
  • [Cites] Mol Pharmacol. 1995 Oct;48(4):758-65 [7476904.001]
  • [Cites] Biochem Pharmacol. 1994 Feb 11;47(4):659-65 [7510479.001]
  • [Cites] Biochem Pharmacol. 1994 Mar 15;47(6):1019-27 [7511899.001]
  • [Cites] Cancer. 1994 May 1;73(9):2432-43 [7513252.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22974-9 [7559435.001]
  • [Cites] Mol Pharmacol. 1995 Sep;48(3):459-71 [7565626.001]
  • [Cites] Biochemistry. 1995 Apr 25;34(16):5660-5 [7727426.001]
  • [Cites] Blood. 1995 Jan 15;85(2):500-9 [7812005.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):566-73 [7834626.001]
  • [Cites] N Engl J Med. 1995 Apr 6;332(14):901-6 [7877646.001]
  • [Cites] Clin Pharmacokinet. 1994 Mar;26(3):190-200 [8194282.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 21;85(14):1154-9 [8320744.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1013-8 [9028333.001]
  • [Cites] Biochem J. 1997 Nov 1;327 ( Pt 3):759-64 [9581553.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):176-81 [9754649.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):348-57 [10023702.001]
  • [Cites] Curr Med Chem. 1999 Apr;6(4):329-52 [10101216.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):775-82 [10498396.001]
  • [Cites] Lancet. 1999 Nov 20;354(9192):1824-5 [10577674.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):24-32 [10598551.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):33-7 [10598552.001]
  • [Cites] Mol Genet Metab. 2000 Aug;70(4):310-5 [10993718.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3705-12 [10999764.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1923-31 [11919253.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Biochem J. 2002 Nov 1;367(Pt 3):629-40 [12144527.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 18):3-17 [12571805.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 18):24-9 [12571807.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7537-52 [14576857.001]
  • (PMID = 21301589.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3033035
  • [Keywords] NOTNLM ; antifolates / cancer / folate metabolism / methotrexate / molecular pharmacology / pemetrexed
  •  go-up   go-down


45. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP: The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood; 2008 May 1;111(9):4668-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemia (T-ALL) is mostly characterized by specific chromosomal abnormalities, some occurring in a mutually exclusive manner that possibly delineate specific T-ALL subgroups.
  • This deletion results in a conserved SET-NUP214 fusion product, which was also identified in the T-ALL cell line LOUCY.
  • We conclude that SET-NUP214 may contribute to the pathogenesis of T-ALL by enforcing T-cell differentiation arrest.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4445-54 [17855633.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):4016-26 [2370860.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Oct 15;49(2):241-8 [2208060.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] Mol Cell Biol. 1992 Apr;12(4):1687-97 [1549122.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Oct;5(3):227-34 [1384675.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1801-8 [8895527.001]
  • [Cites] Mol Cell Biol. 1997 Jan;17(1):495-505 [8972230.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3145-57 [9214632.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17765-70 [15591353.001]
  • [Cites] FEBS Lett. 2005 Jan 31;579(3):757-62 [15670842.001]
  • [Cites] Leukemia. 2005 Mar;19(3):358-66 [15674412.001]
  • [Cites] Cell. 2005 Apr 22;121(2):167-78 [15851025.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1116-27 [16079112.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1948-57 [16107895.001]
  • [Cites] Leukemia. 2006 Jan;20(1):82-6 [16270038.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1123-36 [16618801.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1496-510 [16826225.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1017-24 [16921363.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1212-21 [16956820.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3520-9 [16873670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Leukemia. 2007 Jan;21(1):121-8 [17039236.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S96-104 [12169536.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1157-63 [12764384.001]
  • [Cites] Cell. 2001 Jan 12;104(1):119-30 [11163245.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1197-204 [11830466.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Leukemia. 2004 Feb;18(2):337-40 [14671643.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2373-84 [14993277.001]
  • [Cites] Haematologica. 2007 Feb;92(2):232-5 [17296573.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):654-66 [17569777.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] J Cell Physiol. 2008 Feb;214(2):322-33 [17620317.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):501-7 [15239126.001]
  • (PMID = 18299449.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA11560
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Histone Chaperones; 0 / Homeodomain Proteins; 0 / NUP214 protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion; 0 / SET protein, human; 0 / Transcription Factors; 157907-48-7 / HoxA protein
  • [Other-IDs] NLM/ PMC2343598
  •  go-up   go-down


51. Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L, Superata J, Kurlander R, Singh A, Childs R, Barrett AJ: Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant; 2007 Oct;13(10):1216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.
  • Several studies have shown that a higher lymphocyte count 3-4 weeks after allogeneic stem cell transplantation (SCT) is associated with better transplant outcome.
  • To further explore the relationship between lymphocyte recovery and outcome we analyzed lymphocyte counts and other engraftment parameters in 157 patients with leukemia (48 acute myelogenous leukemia, 80 chronic myelogenous leukemia, and 29 acute lymphoblastic leukemia [ALL]) receiving T cell-depleted myeloablative SCT from an HLA-identical sibling.
  • In multivariate analysis the day 30 absolute lymphocyte count (LC30) above the median of 450/muL was associated with improved survival (71% +/- 5% versus 38% +/- 6%, P < .0001), less relapse (21% +/- 5% versus 44% +/- 7%, P = .009), less nonrelapse mortality (NRM; 9 +/- 3 versus 36% +/- 6%, P < .0001) and less acute graft-versus-host disease (aGVHD) (34% +/- 5% versus 51% +/- 6%, P = .025).
  • The beneficial effect of a higher LC30 influenced outcome in patients with both standard and high-risk disease but did not affect survival and relapse in ALL.
  • These results indicate that LC30 is a surrogate for robust engraftment and identifies an "at-risk" population of patients after T cell-depleted SCT.
  • [MeSH-major] Graft Survival / physiology. Hematopoietic Stem Cell Transplantation / methods. Lymphocyte Count
  • [MeSH-minor] Adolescent. Adult. Biomarkers. Child. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Male. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Predictive Value of Tests. Transplantation, Homologous / methods

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(2):161-72 [9116614.001]
  • [Cites] Bone Marrow Transplant. 1993 Nov;12(5):469-75 [7905331.001]
  • [Cites] Blood. 1998 May 1;91(9):3481-6 [9558408.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(2):183-90 [15531897.001]
  • [Cites] Haematologica. 2005 Jul;90(7):939-48 [15996932.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1688-95 [16131570.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1632-3 [16810198.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Dec;12(12):1318-25 [17162214.001]
  • [Cites] Curr Opin Oncol. 2007 Mar;19(2):142-7 [17272987.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(10):951-6 [11753550.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):23-30 [12815474.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):217-24 [15059145.001]
  • [Cites] Blood. 1987 Feb;69(2):597-604 [3542080.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):301-5 [3552023.001]
  • [Cites] Blood. 1989 Apr;73(5):1351-8 [2495037.001]
  • [Cites] Blood. 1993 Sep 1;82(5):1672-8 [8395913.001]
  • [Cites] Ann Hematol. 1997 Jan;74(1):1-6 [9031607.001]
  • (PMID = 17889359.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA HL006105-01
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS31874; NLM/ PMC3426353
  •  go-up   go-down


52. van Anders SM, Hamilton LD, Schmidt N, Watson NV: Associations between testosterone secretion and sexual activity in women. Horm Behav; 2007 Apr;51(4):477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On three separate nights, they provided pre-activity, post-activity, and next-morning saliva samples and completed brief questionnaires at the last two timepoints.
  • Women's T was higher pre-intercourse than pre-control activity.
  • Women's T was also higher post-intercourse than post-control activity, though the percent change in T from pre- to post-activity was highest for cuddling, then intercourse, then exercise.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320881.001).
  • [ISSN] 0018-506X
  • [Journal-full-title] Hormones and behavior
  • [ISO-abbreviation] Horm Behav
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


53. Valmary S, Danjoux M, Delsol G, Brousset P: [Diagnostic value of anti-terminal deoxynucleotidyl transferase antibody (TdT) in hematologic pathology]. Ann Pathol; 2005 Feb;25(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Intérêt diagnostique de l'anticorps anti-terminal désoxynucleotidyl transférase (TdT) en pathologie hématologique.
  • AIMS: The diagnosis of primitive hematologic malignancies depends on a panel of monoclonal antibodies which is growing over time.
  • The distinction between immature (lymphoblastic lymphoma/acute lymphoblastic leukaemia) and mature lymphoma is sometimes difficult.
  • In this study, we evaluated anti-TdT antibody in the diagnosis and classification of these proliferations.
  • MATERIALS AND METHODS: 13 lesions were examined by immunohistochemistry: 4 B and T lymphoblastic lymphomas, 2 Burkitt's lymphomas, 5 B and T acute lymphoblastic leukemias and 2 acute monoblastic leukemias.
  • TdT is not expressed by mature B or T cell lymphomas such as Burkitt's lymphomas.
  • Significant numbers of cases of acute myeloblastic leukemias are TdT positive but could be easily distinguished from lymphoblastic proliferations.
  • CONCLUSION: Anti-TdT antibody represents a useful marker for differentiating lymphoma/acute lymphoblastic leukemia from other lymphomas.
  • This marker, available in routine diagnosis should be systematically included in the panel of antibodies used for immunophenotyping hematologic malignancies.
  • [MeSH-major] Antibodies. DNA Nucleotidylexotransferase / analysis. DNA Nucleotidylexotransferase / immunology. Hematologic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / diagnosis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Leukemia, Monocytic, Acute / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981929.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


54. Fukushima-Nakase Y, Naoe Y, Taniuchi I, Hosoi H, Sugimoto T, Okuda T: Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development. Blood; 2005 Jun 1;105(11):4298-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development.
  • AML1/Runx1 is a frequent target of human leukemia-associated gene aberration and encodes a transcription factor with nonredundant biologic functions in initial development of definitive hematopoiesis, T-cell development, and steady-state platelet production.
  • To directly determine the presence of functional overlap among runt-related transcription factor (Runx) family molecules, we replaced the C-terminal portion of acute myeloid leukemia 1 (AML1) with that derived from its family members, which are variable in contrast to conserved Runt domain, using the gene knock-in method.
  • However, while AML2 substituted for AML1 could effectively rescue lymphoid lineages, AML3 could not, resulting in a smaller thymus and lymphoid deficiency in peripheral blood.
  • [MeSH-minor] Animals. Blood Cells. Cell Lineage. Cells, Cultured. Chimera / growth & development. Core Binding Factor Alpha 1 Subunit. Core Binding Factor Alpha 2 Subunit. Core Binding Factor Alpha 3 Subunit. DNA-Binding Proteins. Growth and Development. Lymphocytes / cytology. Mice. Myeloid Cells / cytology. Protein Engineering. Protein Structure, Tertiary. Proto-Oncogene Proteins. Thymus Gland / growth & development. Transcription Factor AP-2

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15713794.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 1 Subunit; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor Alpha 3 Subunit; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Runx1 protein, mouse; 0 / Runx2 protein, mouse; 0 / Runx3 protein, mouse; 0 / Transcription Factor AP-2; 0 / Transcription Factors
  •  go-up   go-down


55. Sun K, Li M, Sayers TJ, Welniak LA, Murphy WJ: Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood; 2008 Aug 15;112(4):1522-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
  • Dissociating graft-versus-tumor (GVT) effect from acute graft-versus-host disease (GVHD) still remains a great challenge in allogeneic bone marrow transplantation (allo-BMT).
  • In the current study, the effects of T-cell subsets and their associated cytokines on the efficacy of bortezomib in murine allogeneic BMT were investigated.
  • Importantly, prolonged administration of bortezomib after transplantation of purified CD8(+) T cells resulted in enhanced GVT response, which was dependent on donor CD8(+) T cell-derived IFNgamma.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Sep;9(9):1144-50 [12925844.001]
  • [Cites] Blood. 2003 Jul 1;102(1):303-10 [12637321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5 [15148407.001]
  • [Cites] J Immunol. 1979 Feb;122(2):549-54 [310843.001]
  • [Cites] J Exp Med. 1982 Feb 1;155(2):445-59 [6460073.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5414-20 [2117482.001]
  • [Cites] Blood. 1992 Dec 15;80(12):2964-8 [1467511.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1697-706 [7913943.001]
  • [Cites] J Immunol. 1997 Jun 1;158(11):5185-90 [9164935.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(11):945-52 [9422473.001]
  • [Cites] J Immunother. 1998 Jan;21(1):48-55 [9456436.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4051-5 [9596649.001]
  • [Cites] J Clin Invest. 1998 Nov 1;102(9):1742-8 [9802888.001]
  • [Cites] J Clin Invest. 1998 Dec 15;102(12):2126-35 [9854048.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2192-9 [10498588.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3429-36 [15284108.001]
  • [Cites] Eur J Immunol. 2005 May;35(5):1592-600 [15832287.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1747-67 [16147539.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3293-9 [15961519.001]
  • [Cites] Blood. 2006 Jan 15;107(2):827-34 [16174760.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):1-2 [16412783.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):3-10 [16412784.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Mar;57(3):225-44 [16207532.001]
  • [Cites] Curr Pharm Biotechnol. 2006 Dec;7(6):441-8 [17168660.001]
  • [Cites] Exp Hematol. 2007 Jan;35(1):155-63 [17198884.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):91-7 [17336259.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):340-52 [17438575.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3884-92 [18223170.001]
  • [Cites] Nat Rev Immunol. 2002 Apr;2(4):273-81 [12001998.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1047-55 [10910921.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):604-12 [11128810.001]
  • [Cites] Blood. 2001 May 1;97(9):2886-95 [11313285.001]
  • [Cites] Blood. 2001 Jul 15;98(2):390-7 [11435308.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4207-15 [12010827.001]
  • [Cites] Nat Med. 2002 Jun;8(6):575-81 [12042807.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2440-5 [12424195.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 May;9(5):292-303 [12766879.001]
  • [Cites] Blood Rev. 2003 Dec;17(4):187-94 [14556773.001]
  • (PMID = 18539902.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102282-05; None / None / / R01 CA102282-05; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA102282; United States / NCI NIH HHS / CA / N01CO12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Cytokines; 0 / Pyrazines; 0 / Tumor Necrosis Factor-alpha; 69G8BD63PP / Bortezomib; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2515132
  •  go-up   go-down


56. Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shigeno K, Horii T, Shirai N, Maekawa M, Ohnishi K, Naoe T, Ohno R: Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia; 2005 Aug;19(8):1306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
  • Acute promyelocytic leukemia (APL) cells express a considerable level of CD33, which is a target of gemtuzumab ozogamicin (GO), and a significantly lower level of P-glycoprotein (P-gp).
  • Cells used were an APL cell line in which P-gp was undetectable (NB4), ATRA-resistant NB4 (NB4/RA), NB4 and NB4/RA that had been transfected with MDR-1 cDNA (NB4/MDR and NB4/RA/MDR, respectively), ATO-resistant NB4 (NB4/As) and blast cells from eight patients with clinically ATRA-resistant APL including two patients with ATRA- and ATO-resistant APL.
  • The efficacy of GO was analyzed by (3)H-thymidine incorporation, the dye exclusion test and cell cycle distribution.
  • Leukemia (2005) 19, 1306-1311. doi:10.1038/sj.leu.2403807; published online 26 May 2005.
  • [MeSH-major] Aminoglycosides / pharmacology. Antibodies, Monoclonal / pharmacology. Drug Resistance, Neoplasm. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Arsenicals / pharmacology. Cell Cycle. Cell Proliferation / drug effects. Humans. Oxides / pharmacology. P-Glycoprotein / analysis. Treatment Outcome. Tretinoin / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920495.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Arsenicals; 0 / Oxides; 0 / P-Glycoprotein; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


57. Wenandy L, Kollgaard T, Letsch A, Andersen RS, Stather D, Seremet T, Svane IM, Vindeløv L, Andersen MH, thor Straten P: The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag). Leukemia; 2009 Oct;23(10):1926-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / genetics. Leukemia, Myeloid, Acute / genetics. Minor Histocompatibility Antigens / metabolism. Polymorphism, Single Nucleotide / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Cell Proliferation. Cell Survival. Female. Flow Cytometry. Humans. Polymerase Chain Reaction. T-Lymphocytes, Cytotoxic / immunology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458631.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Minor Histocompatibility Antigens; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


58. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R: A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia; 2007 Mar;21(3):529-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, as in acute leukemias and non-hodgkins lymphoma, we believe it is no longer acceptable to consider MM a single disease entity.
  • As such, the accurate diagnosis of MM subtypes and the adoption of common criteria for the identification and stratification of MM patients has become critical.
  • Although acknowledging that more refined classifications will continue to be developed, we propose that the definition of high-risk disease (any of the t(4;14), t(14;16), t(14;20), deletion 17q13, aneuploidy or deletion chromosome 13 by metaphase cytogenetics, or plasma cell labeling index >3.0) be adopted.

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230230.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, Chiaramonte R, Brini AT, Griffiths M, Maher ER, Zabarovsky E, Latif F: Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics; 2009 Apr 1;4(3):185-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic analysis of childhood acute lymphoblastic leukemia.
  • We used a chromosome 3 wide NotI microarray for identification of epigenetically inactivated genes in childhood acute lymphoblastic leukemia (ALL).
  • The methylation of the above five genes was cancer specific and expression of the genes could be restored in methylated leukemia cell lines treated with 5-aza-2'-deoxycytidine.
  • This is the first report demonstrating frequent epigenetic inactivation of PPP2R3A, FBLN2, THRB, BNC1 and MSX1 in leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Leukemic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Gene Expression Profiling. Gene Silencing. Humans. Molecular Sequence Data. Oligonucleotide Array Sequence Analysis


60. Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T: Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. J Mol Med (Berl); 2010 Mar;88(3):249-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is caused by malignant immature lymphocytes.
  • Given the high plasticity of cells, we searched for leukemia-associated genetic aberrations and immunoglobulin (IG) gene rearrangements in mesenchymal stem cells (MSC) from childhood B-cell precursor ALL patients.
  • MSC from all ten ALL patients analyzed presented the chromosomal translocations that had been detected in leukemia cells (TEL-AML1, E2A-PBX1, or MLL rearrangement).
  • Leukemia-specific IG gene rearrangements were detected in the MSC from three ALL patients.
  • The detection of leukemia-associated genetic aberrations in MSC indicates a clonal relationship between MSC and leukemia cells and suggests their involvement in the pathogenesis and/or pathophysiology of childhood ALL.
  • [MeSH-major] Mesenchymal Stromal Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Mol Med (Berl). 2010 Mar;88(3):219-22 [20135087.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Cell Death Differ. 2009 May;16(5):749-57 [19219067.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Bone. 1996 Nov;19(5):421-8 [8922639.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] Genes Dev. 1991 Mar;5(3):358-68 [1672117.001]
  • [Cites] Nat Rev Immunol. 2006 Feb;6(2):107-16 [16491135.001]
  • [Cites] Blood Rev. 2001 Mar;15(1):49-59 [11333138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):257-68 [17981026.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9142-9 [17909019.001]
  • [Cites] Exp Hematol. 1996 Jan;24(1):1-10 [8536785.001]
  • [Cites] Hum Gene Ther. 1997 Sep 20;8(14 ):1695-700 [9322872.001]
  • [Cites] J Cell Physiol. 1996 Mar;166(3):618-30 [8600166.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Leuk Res. 2006 Aug;30(8):993-1003 [16448696.001]
  • [Cites] PLoS Biol. 2007 Mar;5(3):e43 [17298184.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):497-510 [18598159.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):89-91 [12742162.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):483-95 [18538732.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Blood. 1994 Jun 1;83(11):3271-8 [8193362.001]
  • [Cites] Cell. 2008 Apr 18;133(2):250-64 [18423197.001]
  • [Cites] Blood. 2009 Apr 2;113(14 ):3287-96 [19147788.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1515-27 [19357701.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] J Cell Sci. 2006 Apr 15;119(Pt 8):1477-82 [16551697.001]
  • [Cites] Leukemia. 2009 Apr;23(4):664-72 [19151777.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2238-47 [8161789.001]
  • [Cites] EMBO J. 1997 Jun 16;16(12):3644-54 [9218805.001]
  • [Cites] Blood. 2004 May 15;103(10):3798-804 [14656882.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2753-65 [16931776.001]
  • [Cites] Cell. 2007 Jul 13;130(1):63-75 [17599403.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(5):339-45 [12634724.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1377-88 [17604725.001]
  • [Cites] Methods Mol Med. 2004;91:175-82 [14573937.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):250-9 [15254283.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Lancet. 2000 May 13;355(9216):1688-91 [10905245.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):3-6 [16270377.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):542-5 [11932747.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):413-20 [12163366.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1978-82 [9369435.001]
  • [Cites] Blood. 1971 Jul;38(1):81-6 [5283675.001]
  • [Cites] Cell. 2004 Mar 5;116(5):639-48 [15006347.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • [Cites] Blood. 1978 Jun;51(6):1039-44 [274158.001]
  • (PMID = 20155409.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


61. Advani AS, Gibson SE, Douglas E, Jin T, Zhao X, Kalaycio M, Copelan E, Sobecks R, Sekeres M, Sungren S, Hsi ED: Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer; 2010;10:387
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients.
  • To determine whether HDAC inhibitors may be useful in the treatment of adult acute lymphoblastic leukemia (ALL), we examined the acetylation of histone H4 by immunohistochemistry in newly diagnosed ALL patients and evaluated the impact of acetylation on complete remission (CR) rate, relapse-free survival (RFS), and overall survival (OS).
  • [MeSH-major] Histones / metabolism. Neoplasm Recurrence, Local / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):962-70 [11309347.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:84-100 [12724214.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6 [14734806.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):362-7 [15095300.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):740-8 [18413789.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(1):15-23 [15770522.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1262-6 [15988529.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4051-6 [17827453.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • (PMID = 20663136.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Butyrates; 0 / Histones
  • [Other-IDs] NLM/ PMC2921396
  •  go-up   go-down


62. Foss FM: The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Semin Hematol; 2006 Apr;43(2 Suppl 2):S35-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
  • High-dose chemoradiation conditioning regimens have been associated with a significant incidence of organ toxicity and acute and chronic graft-versus-host disease (GVHD).
  • Recent efforts to diminish the acute transplant-associated toxicities have focused on the development of relatively nontoxic, nonmyeloablative, or less myeloablative conditioning regimens, with the emphasis being predominantly on induction of immunosuppression to enable engraftment.
  • Without ablative chemotherapy, disease control in these regimens is largely relegated to the graft-versus-leukemia/lymphoma (GVL) effect.
  • While the evolution these regimens has resulted in successful engraftment of allogeneic stem cells with minimal toxicity, acute and chronic GVHD occurs in 20% to 50% of patients and remains a major cause of transplant-associated morbidity.
  • Strategies to lower the incidence of acute GVHD have primarily focused on more precise molecular donor/recipient matching, alternative stem cell sources, and T-cell depletion of the graft.
  • While successful in lowering the frequency and severity of GVHD, T-cell-depleted grafts have been associated with compromised the graft-versus-disease effect.
  • While fludarabine and cladribine have been shown to be effective, these agents have been associated with an increased incidence of serious infection and severe acute GVHD.
  • Regimens using pentostatin/extracorporeal photopheresis (ECP)/total body irradiation (TBI) have been shown to be well tolerated and associated with early full donor engraftment with a predominance of donor dendritic cell (DC)2 cells and a low incidence of acute GVHD.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Purine Nucleosides / therapeutic use. Transplantation Conditioning / methods
  • [MeSH-minor] Dendritic Cells / immunology. Dendritic Cells / physiology. Graft vs Host Disease / prevention & control. Hematologic Neoplasms / mortality. Hematologic Neoplasms / therapy. Humans. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549113.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Purine Nucleosides
  • [Number-of-references] 62
  •  go-up   go-down


63. Jabbour EJ, Faderl S, Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clin Proc; 2005 Nov;80(11):1517-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia.
  • Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL).
  • Prognosis has Improved especially in mature B-cell ALL and T-cell lineage ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295033.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


64. McReynolds LJ, Gupta S, Figueroa ME, Mullins MC, Evans T: Smad1 and Smad5 differentially regulate embryonic hematopoiesis. Blood; 2007 Dec 1;110(12):3881-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smad1 and Smad5 differentially regulate embryonic hematopoiesis.
  • The bone morphogenetic protein (BMP) signaling pathway regulates multiple steps of hematopoiesis, mediated through receptor-regulated Smads, including Smad1 and Smad5.
  • Here, we use loss-of-function approaches in zebrafish to compare the roles of Smad1 and Smad5 during embryonic hematopoiesis.
  • We show that knockdown of Smad1 or Smad5 generates distinct and even opposite hematopoietic phenotypes.
  • Embryos depleted for Smad1 have an increased number of primitive erythrocytes, but fail to produce mature embryonic macrophages.
  • In contrast, Smad5-depleted embryos are defective in primitive erythropoiesis, yet have normal numbers of macrophages.
  • Loss of either Smad1 or Smad5 causes a failure in the generation of definitive hematopoietic progenitors.
  • To investigate the mechanism behind these phenotypes, we used rescue experiments and found that Smad5 is unable to rescue the Smad1 loss-of-function phenotype, indicating that the 2 highly related proteins have inherently distinct activities.
  • Microarray experiments revealed that the 2 proteins redundantly regulate the key initiators of the hemato-vascular program, including scl, lmo2, and gfi1.
  • However, each also regulates a remarkably distinct genetic program, with Smad5 uniquely regulating the BMP signaling pathway itself.
  • Our results suggest that specificity of BMP signaling output, with respect to hematopoiesis, can be explained by differential functions of Smad1 and Smad5.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ZFIN: Data: Gene Expression .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Dyn. 1999 Nov;216(3):285-98 [10590480.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5208-14 [17327398.001]
  • [Cites] Development. 2000 Jan;127(2):343-54 [10603351.001]
  • [Cites] Development. 2000 Mar;127(5):957-67 [10662635.001]
  • [Cites] Development. 2001 Mar;128(6):849-58 [11222140.001]
  • [Cites] Development. 2001 Mar;128(6):859-69 [11222141.001]
  • [Cites] Development. 2001 Sep;128(18):3609-21 [11566864.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3087-96 [11698295.001]
  • [Cites] Dev Biol. 2001 Dec 1;240(1):157-67 [11784053.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Dev Biol. 2002 Oct 15;250(2):263-79 [12376102.001]
  • [Cites] Blood. 2003 Jan 1;101(1):124-33 [12393578.001]
  • [Cites] Eur J Biochem. 2003 Feb;270(4):715-25 [12581211.001]
  • [Cites] Blood. 2003 Aug 1;102(3):906-15 [12702499.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3196-205 [12855559.001]
  • [Cites] EMBO J. 2004 Feb 25;23(4):844-56 [14963489.001]
  • [Cites] Stem Cells. 2004;22(4):457-74 [15277693.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7233-46 [15378083.001]
  • [Cites] Nucleic Acids Res. 1993 Mar 11;21(5):1087-95 [8464695.001]
  • [Cites] Genes Dev. 1995 Sep 1;9(17):2105-16 [7657163.001]
  • [Cites] Dev Dyn. 1995 Jul;203(3):253-310 [8589427.001]
  • [Cites] Development. 1996 Dec;123:67-80 [9007230.001]
  • [Cites] Development. 1996 Dec;123:81-93 [9007231.001]
  • [Cites] Development. 1997 Nov;124(22):4457-66 [9409664.001]
  • [Cites] Development. 1999 Apr;126(8):1571-80 [10079220.001]
  • [Cites] Development. 1999 Apr;126(8):1631-42 [10079226.001]
  • [Cites] Development. 1999 May;126(10):2149-59 [10207140.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):73-88 [10525190.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:659-93 [16212511.001]
  • [Cites] Annu Rev Genet. 2005;39:481-501 [16285869.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] Curr Biol. 2006 Mar 7;16(5):506-11 [16527746.001]
  • [Cites] Development. 2006 Jun;133(11):2177-87 [16672337.001]
  • [Cites] Dev Biol. 2006 Aug 1;296(1):104-18 [16765933.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3707-12 [16896158.001]
  • [Cites] Immunity. 2006 Dec;25(6):963-75 [17157041.001]
  • [Cites] Int J Dev Biol. 2007;51(1):79-84 [17183467.001]
  • [Cites] Blood. 2007 Jan 15;109(2):516-23 [16990609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):840-5 [17213321.001]
  • [Cites] FASEB J. 1999 Dec;13(15):2105-24 [10593858.001]
  • (PMID = 17761518.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM056326; United States / NHLBI NIH HHS / HL / R01 HL056182; United States / NIGMS NIH HHS / GM / GM56326; United States / NHLBI NIH HHS / HL / HL056182; United States / NHLBI NIH HHS / HL / R37 HL056182; United States / NIGMS NIH HHS / GM / T32 GM007288; United States / NIGMS NIH HHS / GM / R56 GM056326
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Bone Morphogenetic Proteins; 0 / DNA-Binding Proteins; 0 / Gfi1 protein, zebrafish; 0 / LIM Domain Proteins; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins; 0 / Smad1 Protein; 0 / Smad5 Protein; 0 / Transcription Factors; 0 / Zebrafish Proteins; 0 / lmo2 protein, zebrafish; 0 / smad5 protein, zebrafish; 0 / tal1 protein, zebrafish
  • [Other-IDs] NLM/ PMC2200801
  •  go-up   go-down


65. Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, Skibola CF, Smith MT, Allan JM, Taylor GM, United Kingdom Childhood Cancer Study: Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood; 2010 May 13;115(19):3923-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in the folate metabolic pathway and risk of childhood leukemia.
  • Studies of childhood leukemia and the potential etiologic role of genetic variation in folate metabolism have produced conflicting findings and have often been based on small numbers.
  • We investigated the association between polymorphisms in key folate metabolism enzymes (MTHFR 677 C>T, MTHFR 1298 A>C, SHMT1 1420 C>T, MTR 2756 A>G, TS 1494del6, and TS 28bp repeat) in 939 cases of childhood acute lymphoblastic leukemia (ALL) and 89 cases of acute myeloid leukemia (AML) recruited into the United Kingdom Childhood Cancer Study.
  • These data suggest that genetic variation in methionine synthase could mediate risk of childhood leukemia, either via effects on DNA methylation or via effects on fetal growth and development.
  • [MeSH-major] Folic Acid / metabolism. Genetic Variation / genetics. Glycine Hydroxymethyltransferase / genetics. Leukemia, Myeloid, Acute / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Phosphotransferases (Alcohol Group Acceptor) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 May 15;99(10):3786-91 [11986237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3361-4 [12067974.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):994-9 [12434291.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):154-60 [12827651.001]
  • [Cites] Biotechnol Lett. 2003 Jul;25(13):1031-6 [12889810.001]
  • [Cites] Blood. 2004 Jan 1;103(1):252-7 [12958073.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):423-43 [14977639.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Jul 15;198(2):75-85 [15236946.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):104-17 [15313583.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2155-62 [15198953.001]
  • [Cites] Nucleic Acids Res. 1987 Feb 11;15(3):1259-70 [3029702.001]
  • [Cites] Hum Mol Genet. 1996 Dec;5(12):1867-74 [8968737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3290-5 [9096386.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):523-6 [9198208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Annu Rev Genet. 1998;32:495-519 [9928489.001]
  • [Cites] Mol Genet Metab. 1999 Aug;67(4):317-23 [10444342.001]
  • [Cites] Genet Epidemiol. 1999 Nov;17(4):298-309 [10520212.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4632-42 [15542813.001]
  • [Cites] Blood. 2005 Jan 15;105(2):906-7 [15632215.001]
  • [Cites] Electrophoresis. 2005 Feb;26(3):710-5 [15690424.001]
  • [Cites] BMC Med Genet. 2005 May 27;6:23 [15921520.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Aug;27(8):425-9 [16096524.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2999-3003 [16365025.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):229-32 [16450391.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):147-51 [16123993.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1956-63 [17035405.001]
  • [Cites] Eur J Epidemiol. 2006;21(7):501-10 [16897583.001]
  • [Cites] Leukemia. 2007 Feb;21(2):320-5 [17136115.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1073-102 [10737392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1381-5 [11142426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] Mol Genet Metab. 2001 Jun;73(2):164-72 [11386852.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):616-8 [11736945.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):786-92 [17454638.001]
  • [Cites] BMC Public Health. 2007;7:136 [17605825.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):53-61 [17622527.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2421-30 [18703816.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):276.e1-8 [18771981.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2284-9 [19020309.001]
  • [Cites] Hum Mol Genet. 2009 Nov 1;18(21):4054-65 [19679565.001]
  • [Cites] Cancer Epidemiol. 2009 Oct;33(3-4):257-60 [19736055.001]
  • (PMID = 20101025.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / CA104862; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.2.1 / Glycine Hydroxymethyltransferase; EC 2.1.2.1 / SHMT protein, human; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.100 / 5-methylthioribose kinase
  • [Other-IDs] NLM/ PMC2869556
  •  go-up   go-down


66. Parovichnikova EN, Savchenko VG, Verniuk MA, Vinogradova OA, Misiurin AV, Vorob'ev IA, Domracheva EV, Tikhonova LIu, Rukavitsyn OA, Rossiev VA, Kliasova GA, Turkina AG, Liubimova LS, Mendeleeva LP, Isaev VG: [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]. Ter Arkh; 2005;77(7):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
  • AIM: To develop an original therapeutic strategy in Ph-positive acute lymphoblastic leukemia (ALL).
  • The diagnosis of Ph-positive ALL was established in detection of translocation t(9;22) by standard cytogenetic test or fluorescent hibridization in situ with double signal (D-FISH), or by polymerase chain reaction with reverse transcription (RT-PCR).
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116902.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


67. Owatari S, Otsuka M, Uozumi K, Takeshita T, Hanada S: Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma. Int J Hematol; 2007 Jan;85(1):32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma.
  • We identified 2 cases of secondary acute myeloid leukemia (AML) following adult T-cell leukemia/lymphoma (ATL) in patients who had previously received chemotherapy.
  • In our hospital, only these 2 cases of secondary AML accompanying ATL were identified among 90 cases of acute- or lymphoma-type ATL diagnosed from October 1999 to July 2006.
  • The frequency of coexisting AML and ATL is lower than that reported for acute leukemia coexisting with other lymphoid malignancies.
  • The low frequency of secondary leukemia with ATL may be associated with the short survival times of ATL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid / chemically induced. Leukemia-Lymphoma, Adult T-Cell / complications. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Acute Disease. Alkylating Agents / therapeutic use. Anthracyclines / therapeutic use. Chromosome Aberrations. Female. Humans. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myelomonocytic, Acute / chemically induced. Male. Middle Aged. Podophyllotoxin / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Haematol. 1986 Feb;36(2):127-37 [3518040.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Dec;43(2):227-41 [2598167.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5857-60 [6094001.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):488-94 [9452266.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Leuk Res. 1991;15(2-3):81-90 [2016910.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2505-8 [2720600.001]
  • [Cites] Semin Oncol. 1992 Feb;19(1):47-84 [1736370.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1682-7 [1944468.001]
  • [Cites] Hum Genet. 1997 Jun;99(6):761-5 [9187669.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1748-57 [3783201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Adv Pharmacol. 1990;21:149-83 [2176094.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):53-8 [2177642.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):407-18 [8618232.001]
  • [Cites] Leuk Res. 1992 Nov;16(11):1113-23 [1434747.001]
  • [Cites] Intern Med. 1995 Oct;34(10):947-52 [8563094.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):924-7 [3719557.001]
  • [Cites] Leuk Lymphoma. 1992 Sep;8(1-2):147-55 [1337297.001]
  • [Cites] Jpn J Clin Oncol. 1988 Mar;18(1):33-41 [2895197.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • (PMID = 17261499.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anthracyclines; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


68. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS: Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol; 2008 Jan 15;180(2):699-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD200 is an immunosuppressive molecule overexpressed in multiple hematologic malignancies such as B cell chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.
  • In this report, we seek to select the best candidate to move forward into the clinic and begin to decipher the mechanisms of tumor cell killing by comparing anti-CD200-G1 vs anti-CD200-G2G4 in two related animal models.
  • Separately, in a model that evaluates the effect of the Abs on the immune cell component of the xenograft NOD/SCID hu-mouse model distinctly from the effects of binding to CD200 on tumor cells, we find that the administration of anti-CD200-G1 Abs completely abolished human PBMC-mediated tumor growth inhibition.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178807.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / antigens, CD200
  •  go-up   go-down


69. Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I: WT1 protein expression in childhood acute leukemia. Am J Hematol; 2008 May;83(5):382-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 protein expression in childhood acute leukemia.
  • In patients with acute leukemia, Wilms' tumor gene 1 (WT1) has been used as a target for the detection of minimal residual disease (MRD) by PCR techniques.
  • To determine the relation between expression of WT1 transcripts and of the encoded protein, we examined leukemic cell lines and primary childhood leukemia samples using both real-time quantitative PCR (RQ-PCR) and flow cytometry.
  • WT1 protein was highly expressed in the leukemic cell lines K562, HL-60, PLB 985, KG-1a and CEM.
  • By contrast, 40 primary samples of acute lymphoblastic leukemia (ALL; B-ALL, n = 15 and T-ALL, n = 10) and acute myeloid leukemia (n = 15) expressed low levels of WT1 protein.
  • RQ-PCR detected WT1 transcript levels in the same range as reported in earlier studies in childhood acute leukemia.
  • (ii) WT1 is not a suitable marker for flow cytometric MRD detection in childhood acute leukemia.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. WT1 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Blood Cells / metabolism. Bone Marrow Cells / metabolism. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / metabolism. Child. Child, Preschool. Female. Flow Cytometry. Genes, Wilms Tumor. Humans. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18161786.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  •  go-up   go-down


70. Lu J, Quearry B, Harada H: p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett; 2006 Jun 12;580(14):3539-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells.
  • Treatment of CCRF-CEM (T cell acute lymphoblastic leukemia) cells with the GC, dexamethasone (Dex), activates p38-mitogen activated protein kinase (p38-MAPK) and then induces mRNA transcription and synthesis levels of BIM, a BH3-only pro-apoptotic BCL-2 family member.
  • These findings indicate that BIM induction through p38-MAPK activation is a critical pathway in GC-induced cell death.
  • [MeSH-major] Apoptosis / drug effects. Apoptosis Regulatory Proteins / biosynthesis. Dexamethasone / pharmacology. Leukemia-Lymphoma, Adult T-Cell / pathology. Membrane Proteins / biosynthesis. Proto-Oncogene Proteins / biosynthesis. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Base Sequence. Blotting, Western. Cell Line, Tumor. DNA Primers. Enzyme Activation. Humans

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730715.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / DNA Primers; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


71. Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, Müller-Tidow C, Kolkmeyer A, Büchner T, Serve H, Berdel WE: Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol Cancer Ther; 2006 Dec;5(12):3105-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.
  • In acute myeloid leukemia (AML), receptor tyrosine kinase ligands promote growth and survival and contribute to AML-associated marrow neoangiogenesis.
  • We have tested simultaneous inhibition of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptor signaling by novel indolinone derivatives using 14 myeloid, including 11 human leukemic, cell lines.
  • Compounds inhibited colony formation of all cell lines in a dose-dependent fashion.
  • Inhibitory concentrations for 50% of the colony formation/survival (IC50) for BIBF1000 were <100 nmol/L for 3 of 11, <or=500 nmol/L for 6 of 11, and <1,000 nmol/L for 10 of 11 leukemic cell lines, with one cell line being resistant in the dose range <1,000 nmol/L.
  • BIBF1120 was less effective with 4 of 11 leukemic cell lines being resistant within the dose range <1,000 nmol/L.
  • Testing of myeloid 32D cells transfected with empty vector, wild-type Flt3, or Flt3 carrying an internal tandem duplication mutation revealed higher resistance for the internal tandem duplication mutant.
  • Furthermore, both compounds induced apoptosis in the sensitive cell lines.
  • [MeSH-major] Indoles / pharmacology. Leukemia, Myeloid / drug therapy. Protein Kinase Inhibitors / pharmacology. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Acute Disease. Apoptosis / drug effects. Cell Growth Processes / drug effects. Cell Line, Tumor. Cytarabine / pharmacology. Humans. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation / drug effects. Receptors, Fibroblast Growth Factor / antagonists & inhibitors. Receptors, Fibroblast Growth Factor / blood. Receptors, Fibroblast Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors. Receptors, Platelet-Derived Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / blood. Receptors, Vascular Endothelial Growth Factor / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172413.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIBF 1000; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Receptors, Fibroblast Growth Factor; 04079A1RDZ / Cytarabine; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


72. Ivanoff J, Talme T, Sundqvist KG: The role of chemokines and extracellular matrix components in the migration of T lymphocytes into three-dimensional substrata. Immunology; 2005 Jan;114(1):53-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of chemokines and their interactions with extracellular matrix components (ECM) or the capacity of T cells to migrate into and accumulate within three-dimensional (3D) collagen type 1 substrata was studied.
  • We examined the influence of chemokines and fibronectin on the infiltration properties of non-infiltrative (do not migrate into 3D substrata) and spontaneously infiltrative (migrate into 3D substrata) T-cell lines.
  • Infiltrative and non-infiltrative T-acute lymphocytic leukaemic cell lines exhibited no consistent differences with respect to the expression of various chemokine receptors or beta(1)-integrins.
  • Chemokines presented inside the collagen increased the depth of migration of infiltrative T-cell lines, but did not render non-infiltrative T-cell lines infiltrative, although they augmented the attachment of non-infiltrative T-cell lines to the upper surface of the collagen.
  • The presence of fibronectin inside the collagen did not render non-infiltrative T-cell lines infiltrative, but markedly augmented the migration of 'infiltrative' T-cell lines into collagen.
  • Both infiltrative and non-infiltrative T-cell lines showed migratory responses to chemokines in Boyden assays (migration detected on 2D substrata).
  • These results indicate that the process of T-cell infiltration/migration into 3D substrata depends on a tissue penetration mechanism distinguishable from migration on 2D substrata and that the basic capacity of T cells to infiltrate is independent of chemokines and ECM components applied as attractants.
  • [MeSH-minor] Cell Adhesion / immunology. Cells, Cultured. Collagen / metabolism. Humans. Leukemia, T-Cell / immunology. Receptors, Chemokine / metabolism. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Nov 1;102(9):3262-9 [12855577.001]
  • [Cites] J Cell Biol. 1982 Mar;92(3):747-52 [7085756.001]
  • [Cites] J Cell Biol. 1983 Apr;96(4):1089-96 [6833393.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):282-6 [2166712.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):669-71 [1699135.001]
  • [Cites] Cell. 1991 May 31;65(5):859-73 [1710173.001]
  • [Cites] Immunol Today. 1992 Mar;13(3):106-12 [1622542.001]
  • [Cites] Nature. 1993 Jan 7;361(6407):79-82 [7678446.001]
  • [Cites] Science. 1993 Apr 16;260(5106):355-8 [7682337.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4379-89 [7722295.001]
  • [Cites] FASEB J. 1995 Nov;9(14):1473-81 [7589989.001]
  • [Cites] J Immunol. 1996 Jan 1;156(1):160-7 [8598457.001]
  • [Cites] Cell Immunol. 1996 Feb 1;167(2):269-75 [8603436.001]
  • [Cites] J Immunol. 1996 May 15;156(10):3583-6 [8621890.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):351-62 [8821095.001]
  • [Cites] Crit Rev Immunol. 1995;15(3-4):285-316 [8834453.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):76-84 [8977177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15376-81 [8986819.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):873-82 [9064347.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):963-9 [9064356.001]
  • [Cites] J Leukoc Biol. 1997 Mar;61(3):246-57 [9060447.001]
  • [Cites] Biochem J. 1997 Feb 15;322 ( Pt 1):1-18 [9078236.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3046-53 [9120256.001]
  • [Cites] J Exp Med. 1997 Jul 7;186(1):139-46 [9207008.001]
  • [Cites] J Cell Biol. 1997 Dec 1;139(5):1349-60 [9382879.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):129-34 [9419219.001]
  • [Cites] Eur J Immunol. 1998 Aug;28(8):2331-43 [9710211.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):755-65 [10037796.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):695-711 [10919715.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9201-8 [10734056.001]
  • [Cites] EMBO J. 1997 Aug 1;16(15):4606-16 [9303305.001]
  • [Cites] J Immunol. 2000 Sep 15;165(6):3423-9 [10975862.001]
  • [Cites] Dev Immunol. 2000;7(2-4):67-75 [11097202.001]
  • [Cites] Nat Immunol. 2001 Jun;2(6):508-14 [11376337.001]
  • [Cites] Eur J Immunol. 2002 Feb;32(2):404-12 [11813159.001]
  • [Cites] Biochim Biophys Acta. 1993 Apr 16;1176(3):265-8 [8471628.001]
  • [Cites] Exp Cell Res. 1993 May;206(1):100-10 [8482352.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1821-6 [7684437.001]
  • [Cites] Science. 1993 Jul 2;261(5117):101-3 [8316840.001]
  • [Cites] Immunology. 1993 Dec;80(4):553-60 [8307606.001]
  • [Cites] J Cell Biol. 1994 Jun;125(5):1165-78 [7515069.001]
  • [Cites] Eur J Immunol. 1994 Jan;24(1):273-6 [8020566.001]
  • [Cites] Curr Opin Immunol. 1994 Jun;6(3):380-4 [7917105.001]
  • [Cites] J Cell Biol. 1994 Dec;127(5):1485-95 [7525609.001]
  • [Cites] Science. 1994 Nov 25;266(5189):1395-9 [7973732.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3654-66 [7706709.001]
  • (PMID = 15606795.001).
  • [ISSN] 0019-2805
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 0 / Receptors, Chemokine; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC1782061
  •  go-up   go-down


73. Hu J, Shekhter-Levin S, Shaw PH, Bay C, Kochmar S, Surti U: A case of myelodysplastic syndrome with acquired monosomy 7 in a child with a constitutional t(1;19) and a mosaicism for trisomy 21. Cancer Genet Cytogenet; 2005 Jan 1;156(1):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A mosaic abnormal female karyotype 46,XX, t(1;19)(q42; p13.1)c[12]/ 47,idem,+21c[3]/ 47,idem,-7,+21c,+mar[7] was obtained on G-banded metaphases from unstimulated bone marrow aspirate cell culture.
  • The presence of two cell lines in multiple cultures indicates that the patient is a true low-level mosaic for trisomy 21.
  • Because of the finding of monosomy 7 and a marker chromosome only in the trisomy 21 clone, we conclude that the leukemic clone arose from a hematopoietic precursor with constitutional trisomy 21.
  • Because acute myelogenous leukemia (AML) and MDS with Down syndrome (DS) have distinct biologic and clinical features, the identification of DS patients with a mild or normal phenotype in the AML/MDS population is of fundamental importance for clinical diagnosis and management.


74. Hager-Theodorides AL, Dessens JT, Outram SV, Crompton T: The transcription factor Gli3 regulates differentiation of fetal CD4- CD8- double-negative thymocytes. Blood; 2005 Aug 15;106(4):1296-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of null mutants showed that Gli3 is involved at the transitions from DN1 to CD44+ CD25+ DN (DN2) cell and from DN to CD4+ CD8+ double-positive (DP) cell.
  • Gli3 is required for differentiation from DN to DP thymocyte, after pre-T-cell receptor (TCR) signaling but is not necessary for pre-TCR-induced proliferation or survival.
  • The effect of Gli3 was dose dependent, suggesting its direct involvement in the transcriptional regulation of genes controlling T-cell differentiation during fetal development.
  • [MeSH-major] Antigens, CD / analysis. Cell Differentiation. DNA-Binding Proteins / physiology. Nerve Tissue Proteins / physiology. T-Lymphocytes / cytology. Thymus Gland / cytology. Transcription Factors / physiology
  • [MeSH-minor] Animals. Antigens, CD4. Antigens, CD8. Cell Lineage. Embryo, Mammalian / cytology. Embryo, Mammalian / immunology. Gene Expression Regulation, Developmental. Kruppel-Like Transcription Factors. Mice. Mice, Inbred C57BL. Mice, Mutant Strains


75. Ning BT, Tang YM, Shen HQ, Yang SL, Chen YH, Song H, Shi SW, Qian BQ, Xu WQ: [Preparation and characterization of a directly labeled mouse anti-human CD14 monoclonal antibody ZCH-2F9-FITC]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar;34(2):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The positive cell percentages of 2F9-FITC and CD14-FITC on the monocytes were 84.50% and 90.08%, respectively, while those on lymphocytes were only 0.52% and 1.01%.
  • There was no significant difference between the CD14 expressions with 2F9-FITC and CD14-FITC on each type of leukemia (n=23, t=0.922, P=0.367).
  • CONCLUSION: 2F9-FITC has been successfully prepared and it can be applied in diagnosis and differentiation of monoblastic leukemias.
  • [MeSH-minor] Animals. Cells, Cultured. Flow Cytometry. Fluorescent Antibody Technique. Humans. Leukemia, Lymphoid / pathology. Leukemia, Myeloid, Acute / pathology. Mice. Mice, Inbred BALB C. Monocytes / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812893.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD14; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


76. Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, Schmetzer HM, Salih HR: Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res; 2009 Feb 1;69(3):1037-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans.
  • Here, we studied the role of GITR and its ligand (GITRL) in human acute myeloid leukemia (AML).
  • Surface expression of GITRL was observed on AML cells in six of seven investigated cell lines, and 34 of 60 investigated AML patients whereas healthy CD34(+) cells did not express GITRL.
  • Furthermore, triggering GITR by surface-expressed and sGITRL impaired NK cell cytotoxicity and IFN-gamma production in cocultures with leukemia cells, and NK cell reactivity could be restored by blocking GITR and neutralization of sGITRL and IL-10.
  • Thus, whereas a stimulatory role of the GITR-GITRL system in mouse antitumor immunity has been reported, our data show that in humans GITRL expression subverts NK cell immunosurveillance of AML.
  • Our results provide useful information for therapeutic approaches in AML, which, like haploidentical stem cell transplantation, rely on a sufficient NK cell response.
  • [MeSH-major] Leukemia, Myeloid / immunology. Tumor Necrosis Factors / immunology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Cell Differentiation / immunology. Cell Line, Tumor. Cytokines / immunology. Female. Humans. Immunologic Surveillance / immunology. Interferon-gamma / biosynthesis. Killer Cells, Natural / immunology. Male. Middle Aged. Monocytes / immunology. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155305.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / TNFSF18 protein, human; 0 / Tumor Necrosis Factors; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


77. Steiner M, Attarbaschi A, König M, Gadner H, Haas OA, Mann G: Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.
  • Constitutional trisomy 21 is the most prominent predisposing factor to childhood leukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).
  • Accordingly, they were able to analyze 8 of 10 individuals with DS and a BCP ALL, including 2 who suffered from a TEL/AML1+ leukemia.
  • Based on this observation we concluded that individuals with a constitutional trisomy 21 may have the similar likelihood to develop a TEL/AML1+ leukemia as BCP ALL patients without this specific predisposingfactor.
  • [MeSH-major] Down Syndrome / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • (PMID = 15770827.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


78. Mishra P, Kumar R, Mahapatra M, Sharma S, Dixit A, Chaterjee T, Choudhry DR, Saxena R, Choudhry VP: Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology; 2006 Oct;11(5):335-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculosis in acute leukemia: a clinico-hematological profile.
  • We studied 130 consecutive cases of acute leukemia over a 2-year period and identified 9 cases (6.9%) with active tuberculosis (TB).
  • Eight patients with TB had acute myeloid leukemia (AML).
  • Patients with AML were more likely to develop TB as compared to patients with acute lymphoblastic leukemia (ALL) despite the wider use of steroids and radiotherapy in ALL protocols {OR 4.41 (CI 0.53-36.44)}.
  • However it is not a commonly described infection in acute leukemia and a high index of suspicion is warranted especially in areas endemic for TB.
  • [MeSH-major] Leukemia / complications. Tuberculosis / etiology
  • [MeSH-minor] Acute Disease. Adult. Antitubercular Agents / therapeutic use. Female. Humans. Incidence. Leukemia, Myeloid. Male. Neutropenia. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607583.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


79. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, Forno B, Casucci M, Bernardi M, Peccatori J, Corti C, Bondanza A, Ferrari M, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K: Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med; 2009 Jul 30;361(5):478-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of mismatched HLA in leukemia after stem-cell transplantation.
  • The donor T-cell infusions associated with such transplantation can promote post-transplantation immune reconstitution and control residual disease.
  • METHODS: We identified 43 patients who underwent haploidentical transplantation and infusion of donor T cells for acute myeloid leukemia or myelodysplastic syndrome and conducted post-transplantation studies that included morphologic examination of bone marrow, assessment of hematopoietic chimerism with the use of short-tandem-repeat amplification, and HLA typing.
  • The genomic rearrangements in mutant variants of leukemia were studied with the use of genomic HLA typing, microsatellite mapping, and single-nucleotide-polymorphism arrays.
  • RESULTS: In 5 of 17 patients with leukemia relapse after haploidentical transplantation and infusion of donor T cells, we identified mutant variants of the original leukemic cells.
  • T cells from the donor and the patient after transplantation did not recognize the mutant leukemic cells, whereas the original leukemic cells taken at the time of diagnosis were efficiently recognized and killed.
  • [MeSH-major] Graft vs Leukemia Effect / genetics. HLA Antigens / genetics. Hematopoietic Stem Cell Transplantation. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [CommentIn] N Engl J Med. 2009 Jul 30;361(5):524-5 [19641211.001]
  • (PMID = 19641204.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP08201
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


80. Hao CL, Tang KJ, Chen S, Xing HY, Wang M, Wang JX: [5-Aza-2'-deoxycytidine enhances differentiation and apoptosis induced by phenylbutyrate in Kasumi-1 cells]. Zhonghua Zhong Liu Za Zhi; 2005 Mar;27(3):148-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate whether phenylbutyrate (PB) combined with 5-aza-2'-deoxycytidine (5-Aza-CdR)could inhibit transcription repression and induce t(8;21) acute myelogenous leukemia (AML) Kasumi-1 cells to differentiate and undergo apoptosis.
  • Cellular proliferation was determined by the MTT assay, expression of myeloid-specific differentiation antigen and cell cycles were analyzed by flow cytometry.
  • Cell apoptosis were assessed using AnnexinV/PI staining and flow cytometry.
  • Treatment of Kasumi-1 cells with PB resulted in cell cycle arrest at G(0)/G(1), while combined treatment with PB and 5-Aza-CdR led to cell cycle arrest at G(2)/M.
  • Expression of myeloid cell differentiation antigens CD11b and CD13 induced by PB was enhanced when Kasumi-1 cells were pretreated with low dose of 5-Aza-CdR.
  • CONCLUSION: Phenylbuty rate, when combined with 5-Aza-CdR, inhibits AML cell in vitro proliferation and increases apoptosis in a synergistic fashion.
  • [MeSH-major] Apoptosis / drug effects. Azacitidine / analogs & derivatives. Leukemia, Myeloid / pathology. Phenylbutyrates / pharmacology
  • [MeSH-minor] Acute Disease. Antigens, CD11b / metabolism. Antigens, CD13 / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Drug Synergism. Humans

  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946563.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Phenylbutyrates; 776B62CQ27 / decitabine; EC 3.4.11.2 / Antigens, CD13; M801H13NRU / Azacitidine
  •  go-up   go-down


81. Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, Tanizawa Y: Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med; 2010 Feb;220(2):121-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.
  • The treatment of isolated extramedullary relapse (IEMR) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) poses a challenge for which no standard approach exists.
  • Gemtuzumab ozogamicin (GO) is a recombinant humanized monoclonal antibody, conjugated to calicheamicin, which targets the CD33 antigen that is expressed in acute myelogenous leukemia (AML) blasts.
  • The selectivity of GO for CD33-positive leukemic cells makes it an attractive agent for use in patients with multiple sites of IEMR after allo-HSCT, because GO does not suppress cells responsible for the putative graft-versus-leukemia (GVL) effect.
  • Herein, we describe a 54-year-old male patient who developed AML with multiple sites of extramedullary (EM) relapse after allo-HSCT, and who exhibited apparent donor-derived hematopoiesis in the bone marrow.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Sarcoma, Myeloid / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bone and Bones / radionuclide imaging. CD8-Positive T-Lymphocytes / pathology. Graft vs Leukemia Effect / immunology. Humans. Leukocytes / metabolism. Leukocytes / pathology. Lumbosacral Region / pathology. Lumbosacral Region / radionuclide imaging. Male. Middle Aged. Peroxidase / metabolism. Recurrence. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139663.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


82. Groninger E, Meeuwsen-de Boer T, Koopmans P, Uges D, Sluiter W, Veerman A, Kamps W, de Graaf S: Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer; 2005 Jan;41(1):98-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG).
  • Since vincristine plays a key role in the treatment of childhood acute lymphoblastic leukaemia (ALL), it is worthwhile to explore if efficacy can be improved by individual dose adjustment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine / pharmacokinetics

  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617994.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


83. Joshita S, Kitano K, Nagaya T, Kamijo A, Nakazawa K, Ishida F: Zygomycosis presenting as acute myocardial infarction during hematological malignancies. Intern Med; 2008;47(9):839-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zygomycosis presenting as acute myocardial infarction during hematological malignancies.
  • The second case, a 52-year-old woman with acute lymphoblastic leukemia, developed febrile neutropenia and skin eruptions with induration on the face and extremities during the first induction chemotherapy.
  • She experienced sudden bradycardia with unstable hemodynamics and died of acute myocardial infarction.
  • In light of the above, it should be kept in mind that cardiac zygomycosis might occur in hematologically compromised patients presenting with acute myocardial infarction.
  • [MeSH-major] Coronary Vessels / microbiology. Myelodysplastic Syndromes / microbiology. Myocardial Infarction / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Zygomycosis / complications


84. Ohnuki K, Watanabe Y, Takahashi Y, Kobayashi S, Watanabe S, Ogawa S, Kotani M, Kozono H, Tanabe K, Abe R: Antigen-specific CD4+ effector T cells: analysis of factors regulating clonal expansion and cytokine production: clonal expansion and cytokine production by CD4+ effector T cells. Biochem Biophys Res Commun; 2009 Mar 20;380(4):742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to fully understand T cell-mediated immunity, the mechanisms that regulate clonal expansion and cytokine production by CD4(+) antigen-specific effector T cells in response to a wide range of antigenic stimulation needs clarification.
  • For this purpose, panels of antigen-specific CD4(+) T cell clones with different thresholds for antigen-induced proliferation were generated by repeated stimulation with high- or low-dose antigen.
  • There was no significant difference in antigen-dependent cytokine production by TG40 cells transfected with TCR obtained from either high- or low-dose-responding T cell clones, suggesting that the affinity of TCRs for their ligands is not primary determinant of T cell antigen reactivity.
  • The proliferative responses of all T cell clones to both peptide stimulation and to TCRbeta crosslinking revealed parallel dose-response curves.
  • Finally, the antigen responses of high- and low-peptide-responding T cell clones reveal that clonal expansion and cytokine production of effector T cells occur independently of antigen concentration.
  • [MeSH-minor] Animals. Cell Adhesion Molecules / metabolism. Clone Cells. Flow Cytometry. Mice. Mice, Inbred BALB C. Ovalbumin / immunology. Peptide Fragments / immunology. Receptors, Antigen, T-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address: